EP1322175A2 - Food supplement - Google Patents
Food supplementInfo
- Publication number
- EP1322175A2 EP1322175A2 EP01967544A EP01967544A EP1322175A2 EP 1322175 A2 EP1322175 A2 EP 1322175A2 EP 01967544 A EP01967544 A EP 01967544A EP 01967544 A EP01967544 A EP 01967544A EP 1322175 A2 EP1322175 A2 EP 1322175A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- food supplement
- vitamin
- food
- supplement
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 182
- 238000011282 treatment Methods 0.000 claims abstract description 70
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 64
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 63
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims abstract description 42
- 235000013305 food Nutrition 0.000 claims abstract description 39
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 34
- 229910052711 selenium Inorganic materials 0.000 claims abstract description 30
- 239000011669 selenium Substances 0.000 claims abstract description 30
- 229940088594 vitamin Drugs 0.000 claims abstract description 30
- 229930003231 vitamin Natural products 0.000 claims abstract description 30
- 235000013343 vitamin Nutrition 0.000 claims abstract description 30
- 239000011782 vitamin Substances 0.000 claims abstract description 30
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims abstract description 29
- 230000002265 prevention Effects 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 25
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000005770 Eugenol Substances 0.000 claims abstract description 21
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960002217 eugenol Drugs 0.000 claims abstract description 21
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 20
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 20
- 230000002270 ergogenic effect Effects 0.000 claims abstract description 9
- 239000003075 phytoestrogen Substances 0.000 claims abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 124
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 81
- 230000037396 body weight Effects 0.000 claims description 78
- 235000006708 antioxidants Nutrition 0.000 claims description 63
- 229930003427 Vitamin E Natural products 0.000 claims description 39
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 39
- 229940046009 vitamin E Drugs 0.000 claims description 39
- 235000019165 vitamin E Nutrition 0.000 claims description 39
- 239000011709 vitamin E Substances 0.000 claims description 39
- 241001465754 Metazoa Species 0.000 claims description 38
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 35
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 32
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 32
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 32
- 229930003268 Vitamin C Natural products 0.000 claims description 32
- 235000019154 vitamin C Nutrition 0.000 claims description 32
- 239000011718 vitamin C Substances 0.000 claims description 32
- 241000283073 Equus caballus Species 0.000 claims description 29
- 235000011649 selenium Nutrition 0.000 claims description 29
- 229940091258 selenium supplement Drugs 0.000 claims description 29
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 26
- 235000009337 Spinacia oleracea Nutrition 0.000 claims description 25
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 22
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 21
- 235000013734 beta-carotene Nutrition 0.000 claims description 21
- 239000011648 beta-carotene Substances 0.000 claims description 21
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 21
- 229960002747 betacarotene Drugs 0.000 claims description 21
- 230000004792 oxidative damage Effects 0.000 claims description 21
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 21
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 18
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 18
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 18
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 claims description 18
- 229940035936 ubiquinone Drugs 0.000 claims description 18
- 239000000463 material Substances 0.000 claims description 17
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 16
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 16
- 210000004072 lung Anatomy 0.000 claims description 15
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 240000002234 Allium sativum Species 0.000 claims description 13
- 240000007124 Brassica oleracea Species 0.000 claims description 13
- 235000004611 garlic Nutrition 0.000 claims description 13
- 235000019156 vitamin B Nutrition 0.000 claims description 12
- 239000011720 vitamin B Substances 0.000 claims description 12
- 235000004835 α-tocopherol Nutrition 0.000 claims description 12
- 239000002076 α-tocopherol Substances 0.000 claims description 12
- 235000009421 Myristica fragrans Nutrition 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 10
- 229940014144 folate Drugs 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- 235000019152 folic acid Nutrition 0.000 claims description 10
- 239000011724 folic acid Substances 0.000 claims description 10
- 239000001702 nutmeg Substances 0.000 claims description 10
- 210000002345 respiratory system Anatomy 0.000 claims description 10
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 9
- 235000019482 Palm oil Nutrition 0.000 claims description 9
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 9
- 239000002540 palm oil Substances 0.000 claims description 9
- 241001677259 Acanthophoenix rubra Species 0.000 claims description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 229910052725 zinc Inorganic materials 0.000 claims description 8
- 235000016804 zinc Nutrition 0.000 claims description 8
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 7
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 7
- 244000300264 Spinacia oleracea Species 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 235000011477 liquorice Nutrition 0.000 claims description 7
- 239000011573 trace mineral Substances 0.000 claims description 7
- 235000013619 trace mineral Nutrition 0.000 claims description 7
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 claims description 6
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 claims description 6
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 claims description 6
- 235000021538 Chard Nutrition 0.000 claims description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 5
- 239000011575 calcium Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 235000001465 calcium Nutrition 0.000 claims description 5
- 229940042585 tocopherol acetate Drugs 0.000 claims description 5
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 4
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 4
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 4
- 239000008169 grapeseed oil Substances 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 229910052748 manganese Inorganic materials 0.000 claims description 4
- 239000011572 manganese Substances 0.000 claims description 4
- PMYDPQQPEAYXKD-UHFFFAOYSA-N 3-hydroxy-n-naphthalen-2-ylnaphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(NC(=O)C3=CC4=CC=CC=C4C=C3O)=CC=C21 PMYDPQQPEAYXKD-UHFFFAOYSA-N 0.000 claims description 3
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 3
- 244000223014 Syzygium aromaticum Species 0.000 claims description 3
- 230000007407 health benefit Effects 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 229960001881 sodium selenate Drugs 0.000 claims description 3
- 239000011655 sodium selenate Substances 0.000 claims description 3
- 235000018716 sodium selenate Nutrition 0.000 claims description 3
- 244000270834 Myristica fragrans Species 0.000 claims description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 2
- 238000011443 conventional therapy Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 150000002989 phenols Chemical class 0.000 abstract description 18
- 241000283086 Equidae Species 0.000 description 67
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 52
- 235000010323 ascorbic acid Nutrition 0.000 description 30
- 239000011668 ascorbic acid Substances 0.000 description 30
- 229960005070 ascorbic acid Drugs 0.000 description 29
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 25
- 229960003180 glutathione Drugs 0.000 description 25
- 239000008188 pellet Substances 0.000 description 25
- 229940116269 uric acid Drugs 0.000 description 25
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 24
- 241000196324 Embryophyta Species 0.000 description 20
- 150000003254 radicals Chemical class 0.000 description 19
- 108010024636 Glutathione Proteins 0.000 description 18
- 241000219315 Spinacia Species 0.000 description 18
- 239000012530 fluid Substances 0.000 description 17
- 239000003921 oil Substances 0.000 description 17
- 235000019198 oils Nutrition 0.000 description 17
- 239000013589 supplement Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 235000003969 glutathione Nutrition 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 230000009469 supplementation Effects 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 13
- 229960000984 tocofersolan Drugs 0.000 description 13
- 235000007319 Avena orientalis Nutrition 0.000 description 11
- 244000075850 Avena orientalis Species 0.000 description 11
- -1 alpha-tocopherol radicals Chemical class 0.000 description 11
- 235000005911 diet Nutrition 0.000 description 11
- 230000037213 diet Effects 0.000 description 11
- 230000000670 limiting effect Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 229940087168 alpha tocopherol Drugs 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 235000011331 Brassica Nutrition 0.000 description 9
- 241000219198 Brassica Species 0.000 description 9
- 241000498779 Myristica Species 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 230000002685 pulmonary effect Effects 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- PXGPLTODNUVGFL-NAPLMKITSA-N 8-epi-prostaglandin F2alpha Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@H](O)[C@H]1C\C=C/CCCC(O)=O PXGPLTODNUVGFL-NAPLMKITSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 108010053070 Glutathione Disulfide Proteins 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 7
- 240000008042 Zea mays Species 0.000 description 7
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 6
- 240000003768 Solanum lycopersicum Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 235000021384 green leafy vegetables Nutrition 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000036542 oxidative stress Effects 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 235000010469 Glycine max Nutrition 0.000 description 5
- 244000068988 Glycine max Species 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 235000009973 maize Nutrition 0.000 description 5
- 238000011321 prophylaxis Methods 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- MTMKZABGIQJAEX-UHFFFAOYSA-N 4,4'-sulfonylbis[2-(prop-2-en-1-yl)phenol] Chemical compound C1=C(CC=C)C(O)=CC=C1S(=O)(=O)C1=CC=C(O)C(CC=C)=C1 MTMKZABGIQJAEX-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 238000001839 endoscopy Methods 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 239000003344 environmental pollutant Substances 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 150000002632 lipids Chemical group 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 231100000719 pollutant Toxicity 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 235000007686 potassium Nutrition 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000002516 radical scavenger Substances 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 235000019155 vitamin A Nutrition 0.000 description 4
- 239000011719 vitamin A Substances 0.000 description 4
- 229940045997 vitamin a Drugs 0.000 description 4
- 241000234282 Allium Species 0.000 description 3
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 229940123457 Free radical scavenger Drugs 0.000 description 3
- 108010068370 Glutens Proteins 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 3
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical class [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000005864 Sulphur Chemical class 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 244000128884 Zier Kohl Species 0.000 description 3
- 208000037883 airway inflammation Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 235000014590 basal diet Nutrition 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 229940124630 bronchodilator Drugs 0.000 description 3
- 239000000168 bronchodilator agent Substances 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000010411 cooking Methods 0.000 description 3
- 230000002380 cytological effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 235000012680 lutein Nutrition 0.000 description 3
- 239000001656 lutein Substances 0.000 description 3
- 229960005375 lutein Drugs 0.000 description 3
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 3
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 3
- 235000012661 lycopene Nutrition 0.000 description 3
- 239000001751 lycopene Substances 0.000 description 3
- 229960004999 lycopene Drugs 0.000 description 3
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 235000013379 molasses Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 3
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 3
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 2
- 241001332183 Brassica oleracea var. sabauda Species 0.000 description 2
- 235000004214 Brassica oleracea var. sabauda Nutrition 0.000 description 2
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 2
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 2
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 2
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical class OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 235000013628 Lantana involucrata Nutrition 0.000 description 2
- 240000005183 Lantana involucrata Species 0.000 description 2
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical compound CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 2
- KGEKLUUHTZCSIP-HOSYDEDBSA-N [(1s,4s,6r)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl] acetate Chemical compound C1C[C@]2(C)[C@H](OC(=O)C)C[C@H]1C2(C)C KGEKLUUHTZCSIP-HOSYDEDBSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 2
- ANVAOWXLWRTKGA-XHGAXZNDSA-N all-trans-alpha-carotene Chemical compound CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1C(C)=CCCC1(C)C ANVAOWXLWRTKGA-XHGAXZNDSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 229960004784 allergens Drugs 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000008047 antioxidant nutrient Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000000721 bacterilogical effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000015895 biscuits Nutrition 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- FDSDTBUPSURDBL-LOFNIBRQSA-N canthaxanthin Chemical compound CC=1C(=O)CCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)CCC1(C)C FDSDTBUPSURDBL-LOFNIBRQSA-N 0.000 description 2
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 229910001882 dioxygen Inorganic materials 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000004459 forage Substances 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 208000008384 ileus Diseases 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002535 isoprostanes Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000510 mucolytic effect Effects 0.000 description 2
- 229940066491 mucolytics Drugs 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 229940097156 peroxyl Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 235000017807 phytochemicals Nutrition 0.000 description 2
- 229930000223 plant secondary metabolite Natural products 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000009613 pulmonary function test Methods 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 235000009561 snack bars Nutrition 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000010025 steaming Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940127230 sympathomimetic drug Drugs 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000003519 ventilatory effect Effects 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 235000010930 zeaxanthin Nutrition 0.000 description 2
- 239000001775 zeaxanthin Substances 0.000 description 2
- 229940043269 zeaxanthin Drugs 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- VYIRVAXUEZSDNC-TXDLOWMYSA-N (3R,3'S,5'R)-3,3'-dihydroxy-beta-kappa-caroten-6'-one Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC(=O)[C@]1(C)C[C@@H](O)CC1(C)C VYIRVAXUEZSDNC-TXDLOWMYSA-N 0.000 description 1
- IXELFRRANAOWSF-FNORWQNLSA-N (E)-Ajoene Chemical compound C=CCSS\C=C\CS(=O)CC=C IXELFRRANAOWSF-FNORWQNLSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 102000002281 Adenylate kinase Human genes 0.000 description 1
- 108020000543 Adenylate kinase Proteins 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- XUHLIQGRKRUKPH-GCXOYZPQSA-N Alliin Natural products N[C@H](C[S@@](=O)CC=C)C(O)=O XUHLIQGRKRUKPH-GCXOYZPQSA-N 0.000 description 1
- 108010092760 Alliin lyase Proteins 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000010167 Allium cepa var aggregatum Nutrition 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 235000001270 Allium sibiricum Nutrition 0.000 description 1
- 244000016163 Allium sibiricum Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- RAFGELQLHMBRHD-VFYVRILKSA-N Bixin Natural products COC(=O)C=CC(=C/C=C/C(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(=O)O)/C)C RAFGELQLHMBRHD-VFYVRILKSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- VYIRVAXUEZSDNC-LOFNIBRQSA-N Capsanthyn Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CC(O)CC2(C)C VYIRVAXUEZSDNC-LOFNIBRQSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 description 1
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 239000004217 Citranaxanthin Substances 0.000 description 1
- SLQHGWZKKZPZEK-JKEZLOPUSA-N Citranaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)C)C=CC=C(/C)C=CC1=C(C)CCCC1(C)C SLQHGWZKKZPZEK-JKEZLOPUSA-N 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- 241000854350 Enicospilus group Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 244000287680 Garcinia dulcis Species 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019049 Hair texture abnormal Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 206010028164 Multiple allergies Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000010676 Ocimum basilicum Nutrition 0.000 description 1
- 240000007926 Ocimum gratissimum Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- OOUTWVMJGMVRQF-DOYZGLONSA-N Phoenicoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)C(=O)CCC2(C)C OOUTWVMJGMVRQF-DOYZGLONSA-N 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000003826 Respiratory Acidosis Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- XUHLIQGRKRUKPH-UHFFFAOYSA-N S-allyl-L-cysteine sulfoxide Natural products OC(=O)C(N)CS(=O)CC=C XUHLIQGRKRUKPH-UHFFFAOYSA-N 0.000 description 1
- IDIDJDIHTAOVLG-UHFFFAOYSA-N S-methyl-L-cysteine Natural products CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001134661 Saccharopolyspora rectivirgula Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 240000000785 Tagetes erecta Species 0.000 description 1
- 241000203775 Thermoactinomyces Species 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- IXELFRRANAOWSF-CYBMUJFWSA-N ajoene Natural products C=CCSSC=CC[S@](=O)CC=C IXELFRRANAOWSF-CYBMUJFWSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- XUHLIQGRKRUKPH-DYEAUMGKSA-N alliin Chemical compound OC(=O)[C@@H](N)C[S@@](=O)CC=C XUHLIQGRKRUKPH-DYEAUMGKSA-N 0.000 description 1
- 235000015295 alliin Nutrition 0.000 description 1
- RAFGELQLHMBRHD-UHFFFAOYSA-N alpha-Fuc-(1-2)-beta-Gal-(1-3)-(beta-GlcNAc-(1-6))-GalNAc-ol Natural products COC(=O)C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC(O)=O RAFGELQLHMBRHD-UHFFFAOYSA-N 0.000 description 1
- 239000011795 alpha-carotene Substances 0.000 description 1
- 235000003903 alpha-carotene Nutrition 0.000 description 1
- ANVAOWXLWRTKGA-HLLMEWEMSA-N alpha-carotene Natural products C(=C\C=C\C=C(/C=C/C=C(\C=C\C=1C(C)(C)CCCC=1C)/C)\C)(\C=C\C=C(/C=C/[C@H]1C(C)=CCCC1(C)C)\C)/C ANVAOWXLWRTKGA-HLLMEWEMSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000001670 anatto Substances 0.000 description 1
- 235000019728 animal nutrition Nutrition 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003217 anti-cancerogenic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- UIAFKZKHHVMJGS-UHFFFAOYSA-N beta-resorcylic acid Natural products OC(=O)C1=CC=C(O)C=C1O UIAFKZKHHVMJGS-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- RAFGELQLHMBRHD-SLEZCNMESA-N bixin Chemical compound COC(=O)\C=C\C(\C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/C(O)=O RAFGELQLHMBRHD-SLEZCNMESA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 229940115397 bornyl acetate Drugs 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 235000012682 canthaxanthin Nutrition 0.000 description 1
- 239000001659 canthaxanthin Substances 0.000 description 1
- 229940008033 canthaxanthin Drugs 0.000 description 1
- 235000018889 capsanthin Nutrition 0.000 description 1
- WRANYHFEXGNSND-LOFNIBRQSA-N capsanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC(=O)C2(C)CCC(O)C2(C)C WRANYHFEXGNSND-LOFNIBRQSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000004654 carnosol Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- IXELFRRANAOWSF-UHFFFAOYSA-N cis-ajoene Natural products C=CCSSC=CCS(=O)CC=C IXELFRRANAOWSF-UHFFFAOYSA-N 0.000 description 1
- 235000019247 citranaxanthin Nutrition 0.000 description 1
- PRDJTOVRIHGKNU-ZWERVMMHSA-N citranaxanthin Chemical compound CC(=O)\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C PRDJTOVRIHGKNU-ZWERVMMHSA-N 0.000 description 1
- PRDJTOVRIHGKNU-UHFFFAOYSA-N citranaxanthine Natural products CC(=O)C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C PRDJTOVRIHGKNU-UHFFFAOYSA-N 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000000835 electrochemical detection Methods 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004461 grass silage Substances 0.000 description 1
- 239000004463 hay Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000001053 orange pigment Substances 0.000 description 1
- 150000001451 organic peroxides Chemical class 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 229910052762 osmium Inorganic materials 0.000 description 1
- SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 235000012658 paprika extract Nutrition 0.000 description 1
- 239000001688 paprika extract Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 150000004059 quinone derivatives Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000001054 red pigment Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- TUGDLVFMIQZYPA-UHFFFAOYSA-N tetracopper;tetrazinc Chemical compound [Cu+2].[Cu+2].[Cu+2].[Cu+2].[Zn+2].[Zn+2].[Zn+2].[Zn+2] TUGDLVFMIQZYPA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229940046536 tree pollen allergenic extract Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 150000008122 vinyldithiins Chemical class 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 235000008210 xanthophylls Nutrition 0.000 description 1
- 150000003735 xanthophylls Chemical class 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
- 125000001020 α-tocopherol group Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/20—Feeding-stuffs specially adapted for particular animals for horses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/24—Compounds of alkaline earth metals, e.g. magnesium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- This invention relates to a food supplement comprising one or more antioxidant vitamin in combination with one or more of eugenol, selenium, a carotenoid, a flavenoid, aphyto- estrogen, a proanthrocyanidin, a herbal phenolic compound or ubiquinone.
- the invention further relates to a foodstuff or a food supplement of the invention for use in medicine including aiding the prevention or treatment of oxidative damage especially in the respiratory tract. More preferably this invention relates to a foodstuff or a food supplement of the invention for use in aiding the prevention or treatment of a respiratory disease.
- the invention further relates to the use of the food or food supplement in the manufacture of a foodstuff for aiding the prevention or treatment of oxidative damage more preferably to aid in the prevention or treatment of a respiratory disease.
- the invention further relates to a method for aiding the prevention or treatment of oxidative damage including a method for aiding the prevention or treatment of a respiratory disease.
- a further application of the invention involves the administration of the foodstuff or food supplement as an ergogenic aid.
- Oxidative damage is caused by the action of highly reactive species (such as free radicals or peroxides) on the cells and tissues of the body.
- a free radical is any atom or group of atoms, which has one or more unpaired electrons. Free radicals are uncharged high-energy species that are highly reactive.
- Peroxides are compounds containing linked pairs of oxygen atoms. Organic peroxides can act as sources of free radicals.
- Reactive oxygen species One major source of such reactive species is molecular oxygen, which is converted into a "reactive oxygen species". The loss of an electron from molecular oxygen will produce a free radical species, which reacts with cells or tissue in the body causing damage including lipid peroxidation, which leads to cell death.
- Reactive oxygen species can be produced in the body of an aerobic organism during metabolism, for example by the respiratory burst of phagocytes, mitochondrial oxidative phosphorylation and the xanthine oxidase system.
- reactive oxygen species are produced in the environment, for example by UN light, pollutants or ionising radiation. Agents causing oxidative damage can be inactivated by antioxidant molecules or compounds.
- Antioxidants are typically highly substituted phenols, aromatic amines or sulphur containing molecules, which can occur naturally or can be produced synthetically.
- metal-sequestering agents can act as antioxidants by inactivating metals.
- the body has its own anti-oxidant defences including glutathione, vitamin C, vitamin E, catalase, copper-zinc-superoxide dismutase and uric acid.
- Oxidative damage to the respiratory tract is responsible for causing or exacerbating a number of respiratory disorders. Oxidative stress occurs when the production of reactive oxygen species exceeds the removal of the reactive oxygen species.
- the lung is highly susceptible to oxidative injury due to inhaled reactive oxygen species and exposure to the products of inflammatory cells located in the lungs.
- COPD chronic obstructive pulmonary disease
- Prolonged or persistent respiration dysfunction produces a chronically reduced level of oxygen or a chronically elevated amount of carbon dioxide resulting in respiratory acidosis.
- This respiratory disease has been reported in humans, cats and dogs but is especially prevalent in horses. Symptoms of COPD in horses include decreased exercise tolerance, coughing, mucus hypersecretion, severe dyspnoea and disturbed oxidant/anti oxidant equilibrium.
- COPD causes irreversible changes in the lungs including thickening of the bronchi and bronchioli and collapse of airways. Disturbances in gas exchange in the lung leads to a decrease in oxygen exchange.
- COPD chronic obstructive pulmonary disease
- hay and straw dust a stable environment for instance dust, hay and straw dust, microscopic moulds such as Aspergillus fumigatus, Faenia rectivirgula and Thermoactinomyces vtdgaris and irritating gases (such as ammonia from urine break down) may contribute to the development of the condition.
- Exposure to pollutants in the air and allergies to plant and tree pollen may also play a role in causing this problem in sensitive horses.
- Corticosteroids are used to reduce the inflammation of the airways thereby resolving the clinical signs of the disease. However, the airway inflammation will return following cessation of the therapy if the horse is exposed to offending antigens.
- the use of corticosteroids is accompanied by a number of undesirable side effects. High concentrations of the corticosteroids result in the suppression of the immune system.
- the long-term use of corticosteroids can lead to depression, muscle wasting, long dry hair coat, hyperglycemia, increased risk of laminitis, polydipsia and polyuria.
- Bronchodilators have been used in respiratory diseases to remove airway obstruction in the lungs.
- Anticholinergic agents act by blocking vagally induced bronchospasm, however side effects of the treatment include decreased mucociliary clearance, tachycardia, mydriasis, ileus and excitement.
- Sympathomimetic agents stimulate ⁇ 2 receptors in the large and small airways causing broncodilation.
- ⁇ 2 agonists are not complete and side effects such as trembling, excitement, sweating, ileus, colic and tachycardia can occur as a result of inadvertent stimulation of ⁇ l receptors.
- Phosphodiesterase inhibitors inhibit the breakdown of intracellular cAMP in airway smooth muscle.
- the most commonly used phosphodiesterase inhibitor in horses is theophylline, which works effectively at blood concentrations of 10 ⁇ g/ml.
- the therapeutic level (10 ⁇ g ml blood concentration) and the toxic levels (15 ⁇ g ml blood concentration) are close to each other making theophylline difficult to use clinically.
- mucolytics and expectorants may be useful in cases with excessive quantities of tenaceous mucus in the lower airways however, there is no information showing the efficacy of mucolytics in equine airway disease.
- Mast cell-stabilising agents such as disodium cromglycate have been shown to be effective in prolylaxis of COPD in some horses. In clinical practise, however administration of disodium cromogycate has exhibited mixed results.
- SPAOPD Summer pasture associated obstructive pulmonary disorder
- COPD chronic disease 2019
- SPAOPD affects pastured horses, usually from spring to early autumn with complete remission in winter. Horses which suffer form SPAOPD in summer can also suffer from COPD in winter when they are housed in a stable. Horses with SPAOPD show long term airway hyper-responsiveness. Pulmonary hypersensitivity may occur due to exposure to inhaled pollens or outdoor moulds or due to ingested plant-derived pneumotoxin.
- Treatment of SPAOPD is similar to that used in the management of COPD. These treatments concentrate on the use of environmental management, bronchodilators, anti- inflammatory drugs (especially corticosteroids) and sodium cromglycate.
- adjunct treatment of respiratory disorders will also decrease and in some cases alleviate the symptoms of SPAOPD in horses. It is also proposed that this therapy will reduce the reliance of a horse on conventional drug therapy.
- Horses are usually kept in order to be worked and exercised; for example, horses are kept for recreational or competitive riding.
- oxygen needs of active tissue in the body increases.
- the extra carbon dioxide and heat produced by the body must be removed.
- the rate of respiration will increase.
- Further changes are required to the body,for example circulation must increase to the muscles while adequate circulation is maintained in the rest of the body.
- Free radicals are produced in the environment by ozone, UN light or sources of ionising radiation. Exposure to these forms of free radicals occurs daily as a result of normal day to day living. Exposure is greater in cities or industrial areas where the levels of pollution are high. It is therefore proposed to provide a means of protection against environmental free radical exposure.
- the first aspect of the invention comprises a food supplement comprising one or more antioxidant vitamin in combination with one or more of eugenol, selenium, a carotenoid, a flavenoid, a phyto-oestrogen, a proanthrocyanidin, a herbal phenolic compound or ubiquinone.
- the antioxidant vitamins of the first aspect of the invention are compounds which can inactivate free radical species or the sources of free radicals including reactive oxygen species and hydrogen peroxide.
- antioxidant vitamins include vitamin C, vitamin E and beta-carotene.
- Nitamin C is a water-soluble substance. Nitamin C has a number of important roles in the body. It has an essential role in the maintenance of healthy teeth, gums and bones. It aids the healing of wounds, scar tissue and fractures and strengthens blood vessels. Nitamin C also builds resistance to infection and aids in the prevention and treatment of the common cold. Nitamin C is also one of the major antioxidant nutrients.
- the food supplement of the first aspect of the invention will optionally contain vitamin C at a level of between 60 mg per kilogram body weight and O.lmg per kilogram body weight per day, more preferably 20mg per kilogram body weight and 3mg per kilogram body weight per day, most preferably lOmg or above per kilogram body weight per day.
- the vitamin C according to the first aspect of the invention may be in any form. It may be liquid, semi-solid or solid.
- Nitamin E is a collective term for several biologically similar compounds, including those called tocopherols and tocotrienols, which share the same biological activity.
- the selenium-containing enzyme glutathione peroxidase together with vitamin E helps to protect cells against free radical induced damage.
- Vitamin E acts as a scavenger of free radicals.
- Nitamin C may assist by reducing the tocopheroxyl radicals formed by the scavenging, h addition, vitamin E helps to block lipid peroxidation and may also form an important part of the membrane structure due to its interaction with membrane phospholipids. It has also been suggested that Nitamin E plays an important role in the functioning of the immune system.
- vitamin E in animal tissue is alpha-tocopherol. Nitamin E cannot be synthesised in vivo.
- Forms of vitamin E for the present invention include D-alpha-tocopherol, D-alpha-tocopherol acetate, DL-alpha-tocopherol and DL-alpha-tocopherol acetate.
- Units of vitamin E can be expressed as International Units (IU), where 1 IU of alpha- tocopherol approximates to lmg of alpha-tocopherol.
- Other vitamin E compounds have their IU determined by their biopotency in comparison to alpha-tocopherol as described in McDowell, L.R (1989) Nitamin E: In vitamins in Animal Nutrition, Chapter 4, page 96, Academic Press, UK.
- Nitamin E is a major anti-oxidant nutrient and acts in the body as a free radical scavenger.
- Alpha-tocopherol is the most active anti-oxidant biological form of vitamin E.
- the food supplement of the first aspect of the invention will optionally contain vitamin E at a level of between 20IU per kilogram body weight and HU per kilogram body weight per day, preferably between 10 IU per kilogram body weight and 3 IU per kilogram body weight per day, more preferably 5IU or above per kilogram body weight per day.
- a further useful point in relation to the use of vitamin E in combination with vitamin C is their potential to act synergistically. This may be assisted by the fact that vitamin E is lipid soluble and vitamin C is water-soluble.
- Alpha-tocopherol is known to sit in the lipid membrane. Ascorbate and alpha-tocopherol, for example, interact at the interface between cell membranes or lipoproteins and water. Ascorbic acid rapidly reduces alpha-tocopherol radicals in membranes to regenerate alpha-tocopherol.
- Beta-carotene has strong antioxidant properties and has been shown to be beneficial against selected cancers, cardiovascular diseases, cataracts and age related macular degeneration. Beta-carotene is particularly effective at scavenging peroxyl radicals and is a very potent singlet oxygen quencher at low oxygen tensions. Supplementation of the diet with beta-carotene has been reported to reduce lipid peroxidation.
- the food supplement of the first aspect of the invention will optionally contain beta- carotene as a level of from 1 Omg per kilogram body weight to O.OOlmg per kilogram body weight per day, preferably 0.4mg per kilogram body weight to 0.05mg per kilogram body weight per day, more preferably 0.3mg per kilogram body weight or above per day.
- the antioxidant vitamins (including sources of such vitamins, such as beta-carotene) of the first aspect of the invention are provided in combination with one or more compounds, which exhibit antioxidant or anti-inflammatory properties.
- These compounds include eugenol, selenium, carotenoids, flavenoids, phyto-oestrogens, proanthrocyanidins, herbal phenolic compounds or ubiquinone.
- the food supplement of the first aspect of the invention optionally provides a source of eugenol.
- Eugenol is a naturally occurring aromatic hydrocarbon. It is the active ingredient of spices such as cloves (Osmium spp.), garlic and nutmeg.
- cloves Osmium spp.
- Eugenol has been shown to possess hepatoprotective properties and its administration results in reduced levels of lipid peroxides in vivo.
- eugenol has been shown to protect erythrocytes against free radical damage and eugenol exhibits antioxidant properties.
- Eugenol is provided at levels of between 15mg per kilogram body weight and O.OOlmg per kilogram body weight per day, preferably at levels of between lmg per kilogram body weight and O.Olmg per kilogram body weight per day, more preferably O.lmg per kilogram body weight per day or above.
- the food supplement of the first aspect of the invention optionally provides selenium.
- Selenium is a trace element that functions as a co-factor in the body, specifically as a cofactor within antioxidant metalloenzyme systems.
- selenium is an essential part of the antioxidant selenoenzyme, glutathione peroxidase.
- Selenium acts as an antioxidant (with activity as a free radical scavenger) and has been shown to act in combination with vitamin E. It has now been shown that glutathione levels in horses with COPD, are reduced. Therefore selenium supplementation is of added benefit.
- the food supplement of the first aspect of the invention may provide selenium at a level of from O.OOlmg per kilogram body weight to O.Olmg per kilogram body weight per day, more preferably from 0.006 mg per kilogram body weight to 0.001 mg per kilogram body weight per day, preferably 0.002mg or above per kilogram body weight per day.
- the food supplement of the first aspect of the invention optionally comprises one or more carotenoids.
- the carotenoids are a group of red, orange and yellow pigments predominately found in plant foods, particularly fruit and vegetables, and in the tissues of animals which eat the plants. They are lipophilic compounds. Some carotenoids act as a precursor of vitamin A, . some cannot. This property is unrelated to their antioxidant activity. Carotenoids can act as powerful antioxidants. Carotenoids are absorbed in varying degrees by different animal species. Carotenoids may be classified into two main groups; those based on carotenes and those based on Xanthophylls (which include oxygenated compounds). Common carotenoids include beta-carotene, alpha carotene, lycopene lutein, zeaxanthin and astaxanthin.
- the food supplement of the first aspect of the invention optionally contains one or more flavenoids.
- Flavenoids are found in many plant sources including fruits, vegetables and herbs. They have been reported to have multiple biological effects including their ability to act as antioxidants. Most of the biological roles played by the flavenoids are associated with their transition metal binding capabilities (i.e. iron and copper). Selected flavenoids have been found to have a much higher antioxidant activity than the commonly known antioxidants such as vitamin C or vitamin E. Examples of flavenoids include quercetin, ellagic acid, myricetin and gossypol.
- the food supplement of the first aspect of the invention optionally contains one or more phytoestrogens.
- Phytoestrogens are naturally occurring compounds found in many plants. They are structurally and functionally similar to oestrodiol or produce oestrogenic effects. Phytoestrogens include lignans, isoflavones, counestans and resorcylic acid lactones. These compounds have been reported to possess antioxidant, anticarcinogenic, bactericidal, anti-viral, anti-inflammatory and antihypertensive activities. Sources of phytoestrogens include soya.
- the food supplement of the first aspect of the invention optionally contains one or more of proanthrocyanidins.
- Proanthrocyanidins are potent antioxidant compounds, which in addition to protecting tissue from oxidative injuries can prevent cardiovascular diseases by counteracting the effects of high cholesterol.
- the food supplement of the first aspect of the invention optionally provides a source of herbal phenolic compounds.
- Herbal phenolic compounds are naturally occurring compounds found in plants, especially herbs.
- the compounds are aromatic hydrocarbons, which exhibit antioxidant properties.
- the food supplement of the first aspect of the invention optionally contains ubiquinone (also known as co-enzyme Q).
- Ubiquinone is a co-enzyme that is involved in the formation of ATP in the body.
- the co-enzyme is a quinone derivative that has anti-oxidant activity.
- Natural sources of ubiquinone include green leafy vegetables. Ubiquinone is believed to be non-toxic. It is thought that the coenzyme interacts with vitamin E to regenerates its antioxidant form, thus the administration of vitamin E and ubiquinone may provide a synergistic effect.
- Ubiquinone is believed to stabilise mitochondrial membranes and to help detoxify oxygen free radicals.
- Ubiquinone is provided in this aspect of the invention at a level of between 20mg per kilogram body weight and 0.05mg per kilogram bodyweight per day, more preferably at a level of between 2mg per kilogram bodyweight and 0.3mg per kilogram bodyweight per day and most preferably of 0.5mg or above per kilogram bodyweight per day
- the food supplement of the first aspect of the invention may additionally one or more B vitamins.
- the B vitamins include one or more selected from vitamin B-2
- vitamin B-6 riboflavin
- vitamin B-l pyridoxine
- vitamin B-l thiamine
- vitamin B-12 cobalamin
- vitamin B-3 pantotheic acid and folate.
- Nitamin B-l is involved in metabolism. It aids the digestion of carbohydrates allowing the generation of energy. Thiamine is essential for the normal functioning of the nervous system, muscles and heart.
- Vitamin B-2 (riboflavin) is necessary for carbohydrate, fat and protein metabolism and maintains cell respiration. It aids in the formation of antibodies and red blood cells. It is necessary for the maintenance of good vision, skin, hair and nails and alleviates eye fatigue.
- Nitamin B-6 (pyridoxine) is necessary for the synthesis and breakdown of amino acids and aids in fat and carbohydrate metabolism. It maintains the central nervous system and aids in the formation of antibodies. Nitamin B-6 has been shown to promote healthy skin and reduce muscle spasms, leg cramps, hand numbness, nausea and stiffness of the hands.
- Folate is necessary for both D ⁇ A and R ⁇ A synthesis. It is essential to the formation of red blood cells and aids amino acid metabolism. Folate is preferably provided at a level of between 0.5 mg per kilogram body weight to O.OOlmg per kilogram body weight per day more preferably a level of between 0.25 mg per kilogram body weight to 0.01 mg per kilogram body weight per day.
- the food supplement of the first aspect of the invention can optionally include trace elements such as iron, calcium, magnesium, copper, zinc and manganese.
- the food supplement of the first aspect of the invention optionally includes copper and zinc.
- the components of the first aspect of the invention including the antioxidant vitamins and the antioxidant compounds can be provided by a natural source, a synthetic source or a mixture of one or more natural sources and one or more synthetic sources.
- a portion of the antioxidant vitamin is provided by a synthetic source and a portion of the antioxidant vitamin is provided by a natural source.
- a synthetic source for the purpose of this invention provides the component (for example, the antioxidant vitamin) substantially free of any other material.
- the synthetic source of the component is more than 70% pure, preferably more than 85% pure, more preferably more than 95% pure.
- the synthetic source can be any material which has been prepared from available starting materials by a series of biochemical or chemical reactions. The product of these reactions can then be partially or fully purified.
- the component can be isolated from a natural source. The required component is removed from the other components of the natural source and purified until only the required component is present.
- the synthetic source can be provided alone or can be admixed with other components including other molecules with antioxidant properties, pharmaceutically acceptable excipients, stabilising agents, anti-caking agents, emulsifiers, etc.
- the synthetic source can be provided in combination with a carrier such as silica.
- a carrier such as silica.
- the structure of the synthetic product may correspond exactly to the structure of the component in nature or it can be an analogue of that structure.
- the synthetic product may be provided in a form which can be modified in the body to produce one or more active components (e.g. by the hydrolysis of an ester, etc).
- the antioxidant vitamins can be provided by a synthetic source.
- the structure of the synthetic product may correspond exactly to the structure of the vitamin C, vitamin E or beta-carotene as found in nature or it can be an analogue of those structures.
- the synthetic compound can be provided as a pure form of vitamin C, vitamin E or beta-carotene or can provide vitamin C, vitamin E or beta-carotene in combination with a pharmaceutically acceptable excipient, a stabilising agent, or any other mixing material.
- the synthetic substrate can be in the form of a powder, granule, pellet, tablet, capsule, liquid or semi solid form.
- Nitamin C for the present invention can be obtained from a number of synthetic sources including crystalline ascorbic acid (optionally pure), ethylcellulose coated ascorbic acid, calcium phosphate salts of ascorbic acid, ascorbyl pahnitate, stabilised ascorbyl palmitate, ascorbic acid-2-monophosphate salt or ascorbyl-2-monophosphate with small traces of the disphosphate salt and traces of the triphophate salt or calcium phosphate (Stay-C ® ).
- the vitamin C is provided as Stay-C ® or ascorbyl palmitate.
- Nitamin E for the present invention can be provided by a number of synthetic sources.
- the Nitamin E is provided as DL-alpha-tocopherol or DL-alpha-tocopherol acetate.
- a natural source for the purposes of this invention provides the required component in combination with one or more other compounds.
- the required component is provided within its naturally occurring matrix.
- the natural source of the required component can be an extract or a derivative of a natural source (for example, a plant, animal or mineral).
- the isolated or partially isolated material may then be partially purified by one or more purification steps.
- the component may be provided as part of a raw and unprocessed material.
- the raw unprocessed material may be cooked and/or dried.
- the processed, partially processed or unprocessed material can be reconstituted in the form of a solid, semi-solid or liquid.
- the antioxidant vitamins can be provided by a natural source.
- Nitamin C, vitamin E or beta-carotene can be provided by a natural source containing vitamin C, vitamin E and beta-carotene.
- each of vitamin C, vitamin E or beta-carotene can be provided by a different natural source.
- two or more of vitamin C, vitamin E or beta-carotene can be provided by a particular natural source.
- the antioxidant vitamins can be provided by a natural source, preferably by plant material.
- the plant material can come from any part of a plant (for example, the leaf, root, stem, bark, bulb, fruit, flower or seed) and can be any combination of such parts.
- the plant material can be unprocessed, semi-processed or processed and can be provided as a solid, an extract, an oil, a powder, dried or in solution.
- beta-carotene is provided by one or more of maize meal, broccoli, spinach, carrots, squash, tomato meal, red palm oil, tomato powder or tomato pomace/pulp.
- a preferred source of vitamin E is extracted tocopherols.
- the tocopherols can be from red palm oil or grape seed oil.
- the natural source of vitamin E and beta-carotene is red palm oil.
- the natural source of the antioxidant vitamins is a member of the Brassica (cabbage) family or a leafy green vegetable such as spinach or a combination of both.
- the Brassica family for the present invention includes broccoli, cabbage (including savoy cabbage, red cabbage and Chinese cabbage), cauliflower, brussel sprouts, kale (including curly kale) and chard. More preferably, the natural source is broccoli, curly kale and/or spinach.
- Broccoli is a source of vitamin A, vitamin B-2, vitamin B-6, folate, vitamin C, calcium, potassium and selenium.
- the broccoli can be raw, semi- cooked or cooked.
- Methods of cooking broccoli include baking, steaming and boiling.
- the broccoli may be dried or partially dried. Any form of broccoli for example, raw, semi- cooked or cooked can be dried.
- Preferred forms of dried broccoli include those containing between 0 and 40% w/w water, or between 0 and 10 %, or between 0 and 5%. All preferred features described above for broccoli can also be applied to other members of the Brassica family.
- the addition of members of the Brassica family to the food supplement of the first aspect of the invention will provide additional antioxidant effects.
- the Brassica family contains important sulphur-containing phytochemicals, including glucosinolates and S-methyl- cysteine sulphoxide.
- the phytochemicals have antioxidant capacity and show beneficial effects as anti-cancer agents.
- One embodiment of the invention involves a food supplement containing a level of dried broccoli from 5mg to 50mg per kilogram body weight per day, preferably the food supplement contains a level of 20mg per kilogram body weight per day or above of dried broccoli or an equivalent amount of a semi-dried or fully hydrated form of broccoli.
- Green leafy vegetables for the present invention include spinach (Spinacia oleracea).
- Spinach is high in fibre and contains vitamin A, vitamin B-2, folate, vitamin B-6, vitamin C, vitamin E, potassium and zinc.
- the spinach can be raw or cooked. Methods of cooking spinach include baking, steaming and boiling.
- the spinach can further be dried. Either raw or cooked spinach can be dried.
- Preferred forms of dried spinach include those containing between 0 and 40% w/w water, or between 0 and 10 %, or between 0 and 5%.
- One embodiment of the invention involves a food supplement containing a level of dried spinach from 5mg to 50mg per kilogram body weight per day, preferably the food supplement contains a level of 20mg per kilogram body weight per day or above of dried spinach or an equivalent amount of a semi-dried or fully hydrated form of spinach.
- the food supplement of the first aspect of the invention provides the antioxidant vitamins in combination with one or more of eugenol, selenium, a carotenoid, a flavenoid, a phyto- estrogen, a proanthrocyanidin, a herbal phenolic compound or ubiquinone.
- the antioxidant compounds listed above can be provided by a natural source, a synthetic source or a mixture- of one or more natural sources and one or more synthetic sources.
- a portion of the antioxidant compound is provided by a natural source and a portion of the antioxidant compound is provided by a synthetic source. Definitions of the natural and synthetic sources as discussed for the antioxidant vitamins also apply to the antioxidant compounds.
- eugenol may be provided by one or more of garlic, cloves, or nutmeg. Where eugenol is provided by garlic, it can be provided by the bulb or the shoot or a combination of the bulb and the shoot.
- Garlic is a member of the Allium family. For the purposes of the present invention, garlic can be replaced by any member of the Allium family including onions, shallots, chives and leeks. Garlic has a number of beneficial characteristics.
- the active agents of garlic are a family of sulphur containing compounds, the thioallyl compounds. These include alliin, allicin, alliinase, ajoene and vinyldithiins. The presence of these organosulphur compounds accounts for garlic's antioxidant properties.
- Garlic according to the first aspect of the invention may be in any form. It may be dried, fresh, crushed, in solution, in oil, as a powder, liquid (either as a solution or as an oil) or semi-solid.
- Dried garlic is provided at levels of between 30 mg per kilogram body weight and 1 mg per kilogram body weight per day, preferably at levels of between 20mg per kilogram body weight and 2mg per kilogram bodyweight per day, more preferably at levels of 2mg per kilogram body weight per day and above or an equivalent amount of a semi-dried or fully hydrated form of garlic.
- Nutmegs are widely used in cooking due to their strong bitter warm aromatic taste. They contain eugenol, lignin, stearin, volatile oil, starch, gum and am acid substance. Oil of nutmeg is used medicinally to conceal the taste of various drugs and as a local stimulant to the gastrointestinal tract.
- Nutmeg according to the first aspect of the invention may be in any form. It may be dried, fresh, crushed, in solution, in oil, as a powder, liquid (either as a solution or as an oil) or semi-solid. Dried nutmeg is provided at levels of between 30 mg per kilogram body weight and 1 mg per kilogram body weight per day, preferably at levels of between 20mg per kilogram body weight and 2mg per kilogram bodyweight per day, more preferably at levels of 2mg per kilogram body weight per day and above or an equivalent amount of a semi-dried or fully hydrated form of nutmeg.
- the first aspect of the invention may contain one or more flavenoids from natural and synthetic sources.
- the source of the flavenoid is not limiting. More preferably, the natural source of flavenoids is one or more of rosemary and liquorice.
- Rosemary is a widely used culinary herb.
- the plant contains tannic acid, resin and a volatile oil, which contains Borneol, bornyl acetate and other esters and a camphor derivative.
- Oil of rosemary is used as a tonic, astringent, diaphoretic and stimulant.
- Dried rosemary is provided at levels of between 30 mg per kilogram body weight and 1 mg per kilogram body weight per day, preferably at levels of between 20mg per kilogram body weight and 2mg per kilogram bodyweight per day, more preferably at levels of 2mg per kilogram body weight per day and above or an equivalent amount of a semi-dried or fully hydrated form of rosemary.
- Liquorice has been shown to contain active sponins including glycvrrhizin. These compounds have been reported to have liver-protective effects through their anti-free radical properties. Glycyrrhizin is converted into its aglycone by intestinal flora. Flavonoid aglycones are very bio-available.
- the liquorice may be dried or partially dried, in the form of a powder, in oil, liquid (either as a solution or as an oil), crushed, an extract, fresh or semi-solid.
- Preferred forms of dried liquorice include those containing between 0 and 40% w/w water or between 0 and 10% or between 0 and 5%.
- Dried liquorice is preferably provided at a level of 5mg per kilogram body weight to 0.05mg per kilogram bodyweight per day more preferably lmg per kilogram bodyweight per day or above.
- the first aspect of the invention relates to a food supplement which may contain herbal phenolic compounds.
- the source of the herbal phenolic compounds is not limiting and can include natural and synthetic sources.
- the herbal phenolic compounds can be provided by a natural source such as a plant, more preferably a herb plant.
- the phenolic compounds can be provided by one herb or by a mixture of herbs, for example, one or more of rosemary, nutmeg, oregano, basil and coriander.
- any part of the herb plant can be used (for example, leaf, stem, bark, bulb, root, fruit, flower or seed).
- the herb material can be dried, semi-dried, fresh, crushed, in oil, in solution as a powder, liquid (as a solution or as an oil) or semi-solid.
- the herbal phenolic compound is provided as an extract from a plant.
- the phenolic compound can be extracted and partially or fully purified from the herb.
- the phenolic compounds are obtained from rosemary.
- Phenolics from rosemary include carnosol, rosemanol, carnosic acid and rosemaridiphenol. These phenolic compounds may act as antioxidants, inhibit carcinogenesis or act as anti-inflammatory agents.
- Rosemary according to the first aspect of the invention may be in any form. It may be dried, fresh, crushed, in solution, in oil, as a powder, liquid (either as a solution or as an oil) or semi-solid.
- the first aspect of the invention relates to a food supplement, which may contain a further source of carotenoids.
- the source of carotenoids is not limiting and can include natural and synthetic sources.
- the preferred source is a natural source and includes; marigold meal and lucerne meal (sources of lutein); maize meal, tomato meal, red palm oil, tomato powder, tomato pomace/pulp (sources of beta-carotene and lycopene).
- Sources include oils high in carotenoid levels and pure manufactured carotenoids such as lutein, violaxanthin, cryptoxanthin, bixin, zeaxanthin, apo-EE (Apo-8-carotenic acid ethyl ester), canthaxanthin, citranaxanthin, achinenone, lycopene and capsanthin. More preferably, the source of the carotenoids is red palm oil.
- the first aspect of the invention may optionally comprise proanthrocyanidins.
- the proanthrocyanidins of the present invention can be provided by natural or synthetic sources.
- the source of the proanthrocyanidins is not limiting.
- the proanthrocyanidins are provided by grape seed oil.
- the first aspect of the invention may optionally comprise ubiquinone.
- the source of ubiquinone is not limiting and can include natural or synthetic sources. Natural sources of ubiquinone include green leafy vegetables including spinach and members of the Brassica family.
- the first aspect of the invention may further comprise a source of selenium, wherein the selenium is provided by a synthetic or a natural source.
- the source of the selenium is not limiting. Natural sources of selenium include members of the Brassica family, more preferably broccoli. An alternative natural source of selenium is selenium yeast. Synthetic sources of selenium include any salt or complex of selenium including any organoselenium molecules. Preferably, selenium is provided as sodium selenate.
- the food supplement of the first aspect of the invention optionally contains B-vitamins including folate.
- B-vitamins can be provided by natural or synthetic sources.
- Natural sources of the B vitamins include Brewers yeast.
- Brewers yeast is provided in the food supplement in this aspect of the invention at a level of between 50mg per kilogram body weight and 5mg per kilogram body weight per day, preferably at a level of 20mg per kilogram body weight per day or above.
- the B vitamins may alternatively be provided by plant material.
- the B vitamins may be provided by a member of the Brassica family (broccoli, cabbage (including savoy cabbage, red cabbage and Chinese cabbage), cauliflower, brussel sprouts, kale (including curly kale) and chard), more preferably broccoli, or a green leafy vegetable such as spinach.
- the plant material can be in any form as discussed above.
- the food supplement of the first aspect of the invention can further comprise trace elements such as calcium, magnesium, copper, zinc and manganese.
- the trace elements can be provided by a synthetic or a natural source. Natural sources of such elements (for example potassium and calcium) include members of the Brassica family, more preferably broccoli. Zinc and potassium can be provided by green leafy vegetables such as spinach.
- Synthetic sources of the trace elements include any salt or complex of the metal including any organometallic molecules.
- zinc, copper, magnesium and manganese are provided as the chloride, carbonate or sulphate salts or as the organic chelate.
- the food supplement of the first aspect of the invention can additionally contain ingredients, which enable the food supplement to be formulated in a particular form.
- the food supplement can contain molasses or a molasses/oil mixture for example cane molasses with approximately 6% or above oil such as Molglo (eg. to bind the ingredients together or as a palatability agent) or, oat feed, wheat feed or another suitable filler ingredient (as a filler ingredient).
- the food supplement may also contain a fibre source such as grasses, sugar beet, soya hulls and oats, a fat source such as corn oil, soya oil, processed canola oil, coconut oil, palm oil or sunflower oil and/or a starch source such as cereals (eg. corn, barley, oats).
- the food supplement may be a food.
- the food supplement of the first aspect of the invention can contain a combination of the components discussed above.
- the food supplement comprises:
- a natural source of carotenoids including beta-carotene (for example red palm oil), a natural source of phyto-oestrogens (for example one or more of broccoli and spinach), a natural source of vitamin B including folate (for example, one or more of broccoli or spinach), a synthetic source of folate, a natural source of vitamin C (for example, one or more of broccoli or spinach), a synthetic source of vitamin C (for example Stay-C) a natural source of vitamin E (for example red palm oil), a synthetic source of vitamin E (for example, alpha-tocopherol), a natural source of eugenol (for example one or more of garlic or nutmeg), a natural source of flavenoids (for example one or more of rosemary or liquorice), a synthetic source of selenium (for example sodium selenate), a natural source of proanthrociadins (for example grape seed oil), a natural source of herbal phenolic compounds (for example rosemary).
- beta-carotene for example red palm oil
- the food supplement comprises the following ingredients.
- the food supplement comprises the following ingredients.
- the food supplement of the first aspect of the invention can be provided in varying quantities per day.
- the food supplement can be provided in quantities of between 4kg per day and lOOg per day.
- the food supplement would be provided in quantities of 750g to 150g per day, more preferably 200g or above.
- the figures are pro rata for differently sized horses.
- the food supplement can be fed in quantities of between SOOg and 20g per 100kg bodyweight per day, preferably in quantities of 150g to 30g per 100kg bodyweight per day, more preferably 50g per 100kg bodyweight per day or above.
- Preferred quantities of the food supplement for a horse of a given bodyweight are set out below.
- the above tables 1 and 2 indicate the composition of a food supplement which would be provided in an amount of 250g per day and would be fed to a horse of approximately 500kg bodyweight. It should be appreciated that if the total amount of supplement was to be increased, this would be achieved by increasing the amount of filler ingredients, binders or fibre source while maintaining the absolute amounts of the other components. Conversely, if the total amount of food supplement was to be decreased, the amount of filler ingredients, binders or fibre source would be reduced, whilst maintaining the absolute amounts of the other components.
- the three ingredients, oat feed, maize gluten and soya bean hulls will together typically provide between 20-91% of a supplement of 250g or higher. However, for a low volume supplement the oat feed, maize gluten and soya bean hulls may together be provided at levels of approximately 20% or less of the supplement. For example, for a supplement of approximately lOOg per day, the total amount of oat feed, maize gluten and soya bean hulls may be approximately 6-10% of the supplement.
- the food supplement of the first aspect of the invention can be solid, semi-solid or liquid for example the food supplement could be in the form of a powder, a pellet or a drink.
- the food supplement can be added to the food or administered prior to or after feeding.
- the supplement will be administered together with the standard foodstuff used.
- the mixing may occur when the foodstuff is prepared or packaged or may occur when the foodstuff is provided to the animal.
- the supplement may alternatively be supplied as a topping to the foodstuff.
- the food supplement can be in the form of a food snack or drink (for example, snack bars, biscuits, and sweet products).
- the drink may be aqueous or oil based.
- the food supplement of the first aspect of the invention can be prepared using convention techniques.
- the food supplement is provided as a pellet.
- the ingredients of the food supplement are mixed together and the product mix is passed through a die plate containing several holes of a nominated size (for example from
- Minimal heat is applied to the mixture prior to its entering the mixer to raise the temperature of the mixture to approximately 50°C. Temperatures of 95°C have been used to raise the temperature of the mixture to the required temperature.
- the food supplement can be provided as an extruded pellet. In this process, the mixture enters the extruder where it is heated. By forcing the product along the barrel of the extruder through a series of precision restrictors, the product is exposed to high temperatures and high pressures. The product emerges from the extruder through a shaped die where it expands as the pressure immediately falls to room pressure. The extruded material is then cut to the required length.
- a food supplement of the first aspect of the invention for use in achieving a health benefit.
- the health benefits may be for unhealthy or healthy animals.
- the use can be termed as "medicine” although this term does not necessarily mean that the food supplement is a licensed medicament subject to regulatory authorisation requirements.
- the food supplement may be used in "medicine”.
- the food supplement may be used in aiding the prevention or treatment of oxidative damage.
- the food supplement may be used in aiding the prevention or treatment of an animal suffering from respiratory disease, for example where that disease involves inflammation of the respiratory tract.
- the food supplement of the first aspect of the invention may be for the simultaneous, sequential or separate use in aiding the treatment of an animal suffering from respiratory disease.
- the food supplement of the first aspect is provided to support the health of an animal.
- the food supplement provides antioxidants which are important in maintaining or improving the natural defences of the lung.
- the food supplement can be used to maintain the optimum health of an animal.
- the food supplement can be used in combination with one or more conventional therapies. Administration of the foodstuff may result in an improvement of the symptoms or a slowing of the progression of respiratory disease.
- the terms "aid” and “aiding” mean to decrease or alleviate the symptoms suffered by an animal especially the symptoms of a respiratory disease suffered by a horse.
- This aid may allow the reliance on a drug therapy to be reduced.
- the animal may exhibit less symptoms or the severity of the symptoms may be reduced.
- the animal may exhibit an improved level of fitness or an improved level of well being.
- the food supplement of the first aspect of the invention may be used in aiding the treatment of an animal suffering from chronic obstructive pulmonary disease.
- the food supplement is used where the animal is equine.
- Equine animals for the purposes of this invention include horses, ponies, camels and donkeys. Other mammals include for example human, feline or canine.
- Administration of the food supplement of the first aspect of the invention to an animal will provide an increased level of compounds with antioxidant activity thus reducing oxidative stress to the lung. This will be particularly beneficial where an animal has been or will be or is subjected to an increase in exercise (for example before a competition) or where an animal is exposed to free radicals due to pollution.
- the food supplement may help in maintaining the healthy respiratory system of a horse by supporting or improving the natural defences of the lung.
- the food supplement of the first aspect of the invention can be used to increase the level of antioxidants in animals such as horses, in particular for those in need
- the food supplement is administered to healthy horses in order to supplement their levels of antioxidant and to help protect them against oxidative injury, hi addition, the food supplement can be administered to those animals whose diet is nutritionally deficient in order to provide antioxidant compounds, which are not provided by the diet.
- treatment of COPD in horses involves preventing further attacks by environmental management or the use of prescription medication which can be costly and involves the risk of unwanted side effects.
- Administration of the food supplement of the first aspect of the invention can reduce the need for prescription medication thereby decreasing the risk of side effects to that medication.
- the second aspect of the invention provides a food supplement, which provides an effective prophylaxis or adjunct treatment for COPD in horses.
- the food supplement may be manufactured from natural sources and provides a more natural treatment for this condition.
- a further aspect of the invention provides a food supplement, which provides a contribution to the effective prophylaxis or treatment of asthma.
- Administration of the food supplement of the invention to an individual suffering from asthma will decrease lung inflammation thus decreasing the severity of the symptoms.
- a food supplement containing vitamin C for use in medicine h particular, the third aspect of the invention is for use as described according to the second aspect of the invention. It may be for use in the natural defence of the lungs in a horse (health defence), and for use in aiding in the prevention or the treatment of respiratory disorders in horses.
- the food supplement is for use in aiding the prevention or treatment of horses suffering from COPD.
- the food supplement according to the third aspect of the invention may comprise " selenium, in accordance with the details and preferred features of the first and second aspects of the invention.
- a fourth aspect of the invention provides the use of the food supplement of the first aspect of the invention for the manufacture of a food stuff to aid in the prevention or treatment oxidative damage.
- the oxidative damage may be concentrated in the respiratory tract.
- the fourth aspect of the current invention provides the use of the food supplement of the first aspect of the invention for the manufacture of a food stuff for aiding the prevention or treatment of an animal suffering from a respiratory disease.
- the respiratory disease may involve inflammation of the respiratory tract.
- a fifth aspect of the current invention involves a method of contributing to the prophylaxis or treatment of an animal susceptible to or suffering from oxidative damage.
- the fifth aspect of the invention also relates to a method of contributing to the prophylaxis or treatment of an animal susceptible to or suffering from a respiratory disease.
- this relates to a method of treatment where the respiratory disease involves ah inflammation of the respiratory tract.
- the method may have more general effects throughout the body.
- the method comprises administering to the animal a food supplement of the first aspect of the invention.
- the animal is preferably in need of the prophylaxis or treatment.
- the sixth aspect of the invention provides a food stuff comprising a food supplement of the first aspect of the invention.
- the food stuff can be solid, semi-solid or liquid. It is preferably packaged.
- the packaging may be metal, plastic, paper or card. The amount of moisture in any product may influence the type of packaging, which can be used or is required.
- the food stuff according to the present invention encompasses any product, which an animal consumes in its diet.
- the invention covers standard food products as well as food snacks (for example, snack bars, biscuits and sweet products).
- the food stuff according to the sixth aspect of the invention may be for use in medicine.
- the food stuff may be used to aid in the prevention or treatment of oxidative damage.
- the oxidative damage of this aspect of the invention may be caused by exposure to pollutants, UV light or radiation.
- the oxidative damage may be concentrated in the respiratory tract.
- the food stuff may be used to aid in the prevention or treatment of an animal suffering from respiratory disease.
- the food stuff may be used where the respiratory disease is chronic obstructive pulmonary disorder.
- the food stuff of the sixth aspect of the invention can be prepared using conventional techniques.
- one or more components of the food supplement are mixed with a conventional food stuff.
- the food stuff may then be cooked or chilled and further substances can be added.
- the foodstuff of the sixth aspect of the invention maybe a complete food (i.e. containing all necessary nutrients), a complementary food (which is fed with forage, salt and water), a semi-complementary food (which provides a portion of the necessary nutrients) or a supplementary food (which contains specified amounts of one or more nutrients).
- a seventh aspect of the invention provides the food supplement of the first aspect of the invention or food stuff of the sixth aspect of the invention for administration to an animal as an ergogenic aid.
- the animal is equine.
- An ergogenic aid is any factor, which can increase or improve work production. This could be an increase in speed or endurance or strength.
- the seventh aspect of the invention further provides a method of improving or increasing the work production of an animal comprising administering the ergogenic aid as a food supplement of the first aspect of the invention or as a food stuff of the sixth aspect of the invention.
- the invention further provides a food supplement of the first aspect of the invention or a food stuff of the sixth aspect of the invention for use in the preparation of an ergogenic aid.
- anti-oxidants vitamin C, vitamin E, selenium, zinc or ubiquinone
- vitamin E acts as the defence mechanism while vitamin C regenerates the membrane bound vitamin E.
- Vitamin A and beta-carotene accumulates in tissue membranes and it is believed that these free radical scavengers will react directly with the peroxyl free radicals generated during exercise and serve as additional lipid soluble anti-oxidants. And/or improved oxygen transport due to reduced inflammation within the lung may contribute to any ergogenic effect.
- the horses were fed the same basal diet (normal diet for all the research horses ) for a 6 week adaptation period whilst they were being trained to exercise on the high speed treadmill.
- Vitamin E Blood samples for Vitamin E and markers of systemic oxidative stress, Uric acid, MDA, isoprostanes, Glutathione (GSH, GSSG, TGSH, GRR), Vitamin E, total antioxidant status.
- Horses fed on food supplement A show a lower degree of uric acid production post exercise than the horses fed on the oat hull pellet B.
- Uric acid is a breakdown product of ADP.
- the ADP accumulates triggering the formation of AMP.
- Further metabolism of AMP leads ultimately to uric acid which can be detected in the plasma of horses.
- the accumulation of such end products as uric acid are associated with the onset of fatigue.
- Horses fed on food supplement A showed a significantly reduced heart rate after the third gallop of the exercise treatment compared to horses fed on the oat hull pellet B.
- the horses were randomly divided into two groups of four horses each.
- Group I was supplemented with food supplement A for four weeks, whilst group II was fed pellet B.
- Two hundred fifty gram of either food supplement A or pellet B were fed once daily with one kg of wheat concentrate (molassed oats, pressed corn and pellets). The ingestion of the supplements was systematically verified.
- Venous blood was sampled for analysis of uric acid, glutathione and 8-epi-PGF 2 ⁇ at peak-exercise (E max ), and fifteen (E 15 ) and sixty (E 60 ) minutes after the end of the SET. Airway endoscopy followed by
- Bronchoalveolar lavage was performed immediately after last blood sampling (E 60 ) and BAL uric acid, glutathione and 8-epi-PGF 2 ⁇ were analysed. BAL was randomly performed in one lung side on Day 1 and in the other 24 hours later on Day 2.
- Ventilatory mechanics were measured for two minutes when the horse was breathing normally at rest. It required simultaneous pleural pressure and respiratory airflow measurements, hitrapleural pressure was measured by means of an oesophageal balloon catheter made from a condom sealed over the end of a polyethylene catheter (4 mm inner diameter, 6 mm outer diameter, 220 cm long, VEL, Leuven, Belgium) positioned with its tip in the middle thoracic oesophagus and connected to a pressure transducer (Valydine Ml-45, Valydine Engineering, Northridge, CA, USA). An airtight facemask covered horse's nostrils and mouth. The mask was shaped in order to minimise dead space and to avoid nasal compression.
- a Fleisch pneumotachograph Nr.4 mounted on the facemask was coupled by two identical catheters (4 mm inner diameter, 6 mm outer diameter, 220 cm long, VEL, Leuven, Belgium) to a differential pressure transducer (Valydine DP45-18, Valydine Engineering, Northridge, CA, USA). Respiratory airflow and oesophageal pressure were simultaneously measured and dynamic compliance (C Dyn ), total pulmonary resistance (R ) and maximal pleural pressure changes (Ma ⁇ Ppl) were continuously calculated on a breath-by-breath basis and recorded by a computerised system (Po-Ne- Mah, Gould Instrument Systems, Valley View, OH, USA). Volume and pressure calibrations were performed with a 2 L pump (Medisoft, Dinant, Belgium) and a water manometer, respectively.
- Arterial blood was withdrawn anaerobically from the Arteria carotis communis and analysed, after correction for body temperature, for partial pressure in oxygen (PaO ) and carbon dioxide (PaCO 2 ) (AVL 995, VEL, Leuven, Belgium).
- PaO partial pressure in oxygen
- PaCO 2 carbon dioxide
- Venous blood samples were collected on heparin tubes by jugular puncture on Day 1 and via a jugular catheter placed immediately before the SET on Day 2. All samples were immediately cooled on ice and processed within two minutes after collection. After centrifugation (10 min at 4°C, 900 x g) plasma was aliquoted into 1 ml samples and snap frozen in liquid nitrogen for urea, uric acid and 8-epi-PGF 2 ⁇ determinations. Centrifuged packed blood cells (0.5 mL) were carefully mixed with EDTA (2 mmol in 0.5 mL H 2 O), snap frozen and stored in liquid nitrogen for glutathione analysis.
- BAL fluid was immediately cooled on ice and processed.
- aliquots of 5 mL untreated BAL fluid were stored at -80°C.
- Supernatant of centrifuged BAL (5 minutes, 2500 x g, 4°C) was snap frozen in liquid nitrogen and stored at -80°C for uric acid analysis.
- glutathione analysis methanol was added to BAL (0.7 mL/mL BAL fluid) which was centrifuged for 2 minutes at 3000 x g and 4°C. Supernatant was withdrawn, snap frozen and stored in liquid nitrogen. The remaining BAL fluid was fixed with ethanol (50%) for cytological analysis.
- the horses performed for fifty minutes a SET on a treadmill in a ventilated and air conditioned room (ambient temperature 18 ⁇ 3°C, relative humidity 55-60% ).
- the SET consisted in a warm-up followed by three gallop steps which were interrupted by periods of trot.
- the SET was finished by a cool down walking.
- Exercise monitoring was performed at the end of each gallop step by telemetric heart rate recording (Life Scope Monitor, Nihon Kohden, Bretford, Middlesex, UK) and venous lactate determination (Accusport, Boehringer Mannheim, Mannheim, Germany). After the cool down walk, rectal temperature and venous packed cell volume (PCV) were measured.
- PCV venous packed cell volume
- Plasma urea and uric acid were determined spectrophotometrically by the Sigma kit 66-20 BUN Endpoint and uric acid kit 685 (Sigma Diagnostics, St. Louis, USA), respectively.
- the haemolysate glutathione was analysed by high performance liquid chromatography (HPLC.
- Plasma 8-epi-PGF 2 ⁇ was analysed by an EIA kit (R&D Systems, Abingdon UK).
- BAL urea was spectrophotometrically determined according to the method of Rennard et al (1986) by use of the Sigma kit 66-20 BUN Endpoint (Sigma Diagnostics, St Louis, USA). Uric acid was analysed by HPLC. GSH and GSSG in BAL were measured by use of HPLC and GRR was calculated. 8-Epi-PGF 2 ⁇ in BAL was purified and concentrated (C 18 column, Bond Elut, Varian, Harbor City, CA, USA) before being analysed by an EIA kit (Cayman, Abingdon, UK). Differential cell count of BAL cells was performed after centrifugation and Papanicolaou staining.
- PCV packed cell volume
- NA not assessed.
- 8-Epi-PGF 2 ⁇ was not modified by either food supplement A (B) or pellet B (D).
- the concentrations of BAL uric acid, glutathione and 8-epi-PGF 2 ⁇ were expressed per ml of pulmonary epithelial lining fluid (PELF).
- Bronchoalveolar differential cell count was influenced neither by food supplement A (B) nor by pellet B (D).
- Ascorbic acid in bronchoalveolar lavage and plasma were analysed by HPLC using electrochemical detection and UN detection respectively. Bronchoalveolar lavage concentrations of ascorbic acid were corrected to mmol.1 "1 of epithelial lining fluid using plasma and bronchoalveolar lavage urea concentrations.
- the concentration of ascorbic acid in epithelial lining fluid of healthy horses is 20 - 30 times greater than those of reduced glutathione previously reported in horses.
- ascorbic acid is a major antioxidant in equine lung fluid lining and horses suffering from COPD appear to have markedly reduced levels in both plasma and bronchoalveolar lavage.
- COPD horses have shown reduced levels of other antioxidants such as glutathione.
- Ponies were studied in stable pairs and each pair received three treatments: 1) - Control (C); 2) Ascorbyl palmitate (AP; fed at 57.1 mg/day per kg BW); 3) Stabilised ascorbic acid (STAY-C; fed at 57.1 mg/day per kg BW). Doses were chosen to ensure equivalent ascorbic acid levels. Each treatment lasted two weeks and was followed by a washout period of two weeks before the next treatment period. Every two weeks BAL was performed in the right and left lung. On the day following BAL, blood samples were collected before and every hour following feeding up to 8 hours to determine plasma bioavailability.
- TW tracheal wash
- BAL bronchoalveolar lavage
- the placebo supplement did not alter ELF AA (1.2 1. lmmol/1 versus 1.3 *0.5rhmol/l). Neither plasma nor ELF AA were significantly changed one hour after the exercise test compared to resting concentrations after either the antioxidant supplement or the placebo.
- antioxidant supplementation caused increases in plasma levels of ascorbic acid and in ELF ascorbic acid levels.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Obesity (AREA)
- Physiology (AREA)
- Birds (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
Abstract
The present invention provides a food supplement and method for aiding in the prevention or treatment of a respiratory disease. The present invention further provides the foodstuff or food supplement as an ergogenic aid. The food or food supplement of the present invention comprises one or more antioxidant vitamins in combination with one or more of eugenol, selenium, a carotenoid, a flavenoid, a phyto-estrogen, a proanthrocyanidin herbal phenolic compound or urbiquinone.
Description
FOOD SUPPLEMENT
This invention relates to a food supplement comprising one or more antioxidant vitamin in combination with one or more of eugenol, selenium, a carotenoid, a flavenoid, aphyto- estrogen, a proanthrocyanidin, a herbal phenolic compound or ubiquinone. The invention further relates to a foodstuff or a food supplement of the invention for use in medicine including aiding the prevention or treatment of oxidative damage especially in the respiratory tract. More preferably this invention relates to a foodstuff or a food supplement of the invention for use in aiding the prevention or treatment of a respiratory disease. The invention further relates to the use of the food or food supplement in the manufacture of a foodstuff for aiding the prevention or treatment of oxidative damage more preferably to aid in the prevention or treatment of a respiratory disease. The invention further relates to a method for aiding the prevention or treatment of oxidative damage including a method for aiding the prevention or treatment of a respiratory disease. A further application of the invention involves the administration of the foodstuff or food supplement as an ergogenic aid.
Oxidative damage is caused by the action of highly reactive species (such as free radicals or peroxides) on the cells and tissues of the body. A free radical is any atom or group of atoms, which has one or more unpaired electrons. Free radicals are uncharged high-energy species that are highly reactive. Peroxides are compounds containing linked pairs of oxygen atoms. Organic peroxides can act as sources of free radicals.
One major source of such reactive species is molecular oxygen, which is converted into a "reactive oxygen species". The loss of an electron from molecular oxygen will produce a free radical species, which reacts with cells or tissue in the body causing damage including lipid peroxidation, which leads to cell death. Reactive oxygen species can be produced in the body of an aerobic organism during metabolism, for example by the respiratory burst of phagocytes, mitochondrial oxidative phosphorylation and the xanthine oxidase system. hi addition, reactive oxygen species are produced in the environment, for example by UN light, pollutants or ionising radiation.
Agents causing oxidative damage can be inactivated by antioxidant molecules or compounds. Antioxidants are typically highly substituted phenols, aromatic amines or sulphur containing molecules, which can occur naturally or can be produced synthetically. In addition, metal-sequestering agents can act as antioxidants by inactivating metals. The body has its own anti-oxidant defences including glutathione, vitamin C, vitamin E, catalase, copper-zinc-superoxide dismutase and uric acid.
Exposure of the body to agents causing oxidative damage results in inflammation, auto immune diseases, cancers, muscle disorders, lung inflammation and general ageing. Oxidative damage to the respiratory tract is responsible for causing or exacerbating a number of respiratory disorders. Oxidative stress occurs when the production of reactive oxygen species exceeds the removal of the reactive oxygen species. The lung is highly susceptible to oxidative injury due to inhaled reactive oxygen species and exposure to the products of inflammatory cells located in the lungs.
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease, which results in respiratory dysfunction. Prolonged or persistent respiration dysfunction produces a chronically reduced level of oxygen or a chronically elevated amount of carbon dioxide resulting in respiratory acidosis. This respiratory disease has been reported in humans, cats and dogs but is especially prevalent in horses. Symptoms of COPD in horses include decreased exercise tolerance, coughing, mucus hypersecretion, severe dyspnoea and disturbed oxidant/anti oxidant equilibrium.
COPD causes irreversible changes in the lungs including thickening of the bronchi and bronchioli and collapse of airways. Disturbances in gas exchange in the lung leads to a decrease in oxygen exchange.
The cause of COPD in horses is believed to multifactorial. COPD is comparatively rare in tropical or subtropical countries where horses are more commonly kept outside. It is generally believed that exposure to materials in a stable environment for instance dust, hay and straw dust, microscopic moulds such as Aspergillus fumigatus, Faenia rectivirgula and Thermoactinomyces vtdgaris and irritating gases (such as ammonia from urine break down) may contribute to the development of the condition. Exposure to pollutants in the
air and allergies to plant and tree pollen may also play a role in causing this problem in sensitive horses.
Treatment of COPD is purely palliative, as there is currently no cure. The management of COPD concentrates on preventing further attacks. This environmental management approach includes keeping the horse outside. Where a horse must be kept inside, good ventilation is essential in order to minimise exposure to dust, pollutants etc and the use of dustfree grains, appropriate bedding or moistening food before feeding helps to avoid further attacks. This approach is the most effective method of alleviating the symptoms of COPD but owner compliance is a problem.
i moderate or severe cases of COPD, it is necessary to treat the horse with prescription medication. Corticosteroids are used to reduce the inflammation of the airways thereby resolving the clinical signs of the disease. However, the airway inflammation will return following cessation of the therapy if the horse is exposed to offending antigens. The use of corticosteroids is accompanied by a number of undesirable side effects. High concentrations of the corticosteroids result in the suppression of the immune system. The long-term use of corticosteroids can lead to depression, muscle wasting, long dry hair coat, hyperglycemia, increased risk of laminitis, polydipsia and polyuria.
Therefore any treatment or therapy which decreases the concentration of corticosteroids necessary to treat COPD will be beneficial.
Bronchodilators have been used in respiratory diseases to remove airway obstruction in the lungs. There are three major classes of bronchodilators; anticholinergic agents, sympathomimetic agents and phosphodiesterase inhibitors.
Anticholinergic agents, such as atropine, act by blocking vagally induced bronchospasm, however side effects of the treatment include decreased mucociliary clearance, tachycardia, mydriasis, ileus and excitement.
Sympathomimetic agents stimulate β2 receptors in the large and small airways causing broncodilation. However the specificity of β2 agonists is not complete and side effects
such as trembling, excitement, sweating, ileus, colic and tachycardia can occur as a result of inadvertent stimulation of βl receptors.
Phosphodiesterase inhibitors inhibit the breakdown of intracellular cAMP in airway smooth muscle. The most commonly used phosphodiesterase inhibitor in horses is theophylline, which works effectively at blood concentrations of 10 μg/ml. However the therapeutic level (10 μg ml blood concentration) and the toxic levels (15 μg ml blood concentration) are close to each other making theophylline difficult to use clinically.
The use of mucolytics and expectorants may be useful in cases with excessive quantities of tenaceous mucus in the lower airways however, there is no information showing the efficacy of mucolytics in equine airway disease.
Mast cell-stabilising agents such as disodium cromglycate have been shown to be effective in prolylaxis of COPD in some horses. In clinical practise, however administration of disodium cromogycate has exhibited mixed results.
It has been suggested that immunotherapy may be helpful in some cases of COPD, producing hyposensitisation to offending allergens. However, the identification of the relevant allergens and the presence of multiple allergies in individual horses limit the effectiveness of this treatment.
The use of conventional drug therapies can be effective in the treatment of COPD. However these therapies are costly and can have some undesirable side effects. It is therefore proposed to find an adjunct treatment to respiratory disorders including COPD in horses. It is proposed that this therapy will decrease and in some cases alleviate the symptoms of COPD in horses, i addition, it is proposed that this therapy will reduce the reliance of a horse on conventional drug therapies.
Summer pasture associated obstructive pulmonary disorder (SPAOPD) exhibits similar clinicopathology to COPD. SPAOPD affects pastured horses, usually from spring to early autumn with complete remission in winter. Horses which suffer form SPAOPD in summer can also suffer from COPD in winter when they are housed in a stable.
Horses with SPAOPD show long term airway hyper-responsiveness. Pulmonary hypersensitivity may occur due to exposure to inhaled pollens or outdoor moulds or due to ingested plant-derived pneumotoxin.
Treatment of SPAOPD is similar to that used in the management of COPD. These treatments concentrate on the use of environmental management, bronchodilators, anti- inflammatory drugs (especially corticosteroids) and sodium cromglycate.
It is therefore proposed that the adjunct treatment of respiratory disorders will also decrease and in some cases alleviate the symptoms of SPAOPD in horses. It is also proposed that this therapy will reduce the reliance of a horse on conventional drug therapy.
Horses are usually kept in order to be worked and exercised; for example, horses are kept for recreational or competitive riding. During exercise the oxygen needs of active tissue in the body increases. At the same time, the extra carbon dioxide and heat produced by the body must be removed. To this end, the rate of respiration will increase. Further changes are required to the body,for example circulation must increase to the muscles while adequate circulation is maintained in the rest of the body.
During exercise, the energy requirement increases and ATP is hydrolysed to ADP and inorganic phosphate in order to meet this demand. Regeneration of ATP from ADP is facilitated by creatine phosphate. Creatine phosphate itself is resynthesised using energy derived from the oxidation of carbohydrates, fats and proteins within the mitochondria.
If the resynthesis of creatine phosphate becomes limiting then there will be a build up of ADP and a reduced power output. During intense exercise, when muscle phosphocreatine stores are becoming limited, ADP accumulation starts. Increased levels of ADP trigger the myokinase reaction in which two molecules of ADP form one molecule of AMP. The AMP is further deaminated to IMP and metabolised via inosine, hypoxanthine, and xanthine to uric acid. The decline in muscle ATP is mirrored by the postexercise appearance of the end products of this pathway including uric acid into the plasma of the horse. These processes are associated with the onset of fatigue. IMP can be reammated to
AMP especially at the onset of recovery. Degradation of IMP to uric acid is one of several routes by which highly reactive free radicals are formed and which during exercise may challenge the anti-oxidant defences. Other free radicals will be produced through increased rates of metabolism and respiration.
Thus, it is proposed to provide a means of lessening the oxidative stress produced by exercise. The reduction in oxidative stress should allow a horse to recover more quickly from the exercise thus improving the welfare of the horse.
Free radicals are produced in the environment by ozone, UN light or sources of ionising radiation. Exposure to these forms of free radicals occurs daily as a result of normal day to day living. Exposure is greater in cities or industrial areas where the levels of pollution are high. It is therefore proposed to provide a means of protection against environmental free radical exposure.
The first aspect of the invention comprises a food supplement comprising one or more antioxidant vitamin in combination with one or more of eugenol, selenium, a carotenoid, a flavenoid, a phyto-oestrogen, a proanthrocyanidin, a herbal phenolic compound or ubiquinone.
The antioxidant vitamins of the first aspect of the invention are compounds which can inactivate free radical species or the sources of free radicals including reactive oxygen species and hydrogen peroxide. Examples of such antioxidant vitamins include vitamin C, vitamin E and beta-carotene.
Nitamin C is a water-soluble substance. Nitamin C has a number of important roles in the body. It has an essential role in the maintenance of healthy teeth, gums and bones. It aids the healing of wounds, scar tissue and fractures and strengthens blood vessels. Nitamin C also builds resistance to infection and aids in the prevention and treatment of the common cold. Nitamin C is also one of the major antioxidant nutrients.
The food supplement of the first aspect of the invention will optionally contain vitamin C at a level of between 60 mg per kilogram body weight and O.lmg per kilogram body
weight per day, more preferably 20mg per kilogram body weight and 3mg per kilogram body weight per day, most preferably lOmg or above per kilogram body weight per day.
The vitamin C according to the first aspect of the invention may be in any form. It may be liquid, semi-solid or solid.
Nitamin E is a collective term for several biologically similar compounds, including those called tocopherols and tocotrienols, which share the same biological activity. The selenium-containing enzyme glutathione peroxidase together with vitamin E helps to protect cells against free radical induced damage. Vitamin E acts as a scavenger of free radicals. Nitamin C may assist by reducing the tocopheroxyl radicals formed by the scavenging, h addition, vitamin E helps to block lipid peroxidation and may also form an important part of the membrane structure due to its interaction with membrane phospholipids. It has also been suggested that Nitamin E plays an important role in the functioning of the immune system. The most biologically active biological form of vitamin
E in animal tissue is alpha-tocopherol. Nitamin E cannot be synthesised in vivo. Forms of vitamin E for the present invention include D-alpha-tocopherol, D-alpha-tocopherol acetate, DL-alpha-tocopherol and DL-alpha-tocopherol acetate.
Units of vitamin E can be expressed as International Units (IU), where 1 IU of alpha- tocopherol approximates to lmg of alpha-tocopherol. Other vitamin E compounds have their IU determined by their biopotency in comparison to alpha-tocopherol as described in McDowell, L.R (1989) Nitamin E: In vitamins in Animal Nutrition, Chapter 4, page 96, Academic Press, UK.
Nitamin E is a major anti-oxidant nutrient and acts in the body as a free radical scavenger. Alpha-tocopherol is the most active anti-oxidant biological form of vitamin E.
The food supplement of the first aspect of the invention will optionally contain vitamin E at a level of between 20IU per kilogram body weight and HU per kilogram body weight per day, preferably between 10 IU per kilogram body weight and 3 IU per kilogram body weight per day, more preferably 5IU or above per kilogram body weight per day.
A further useful point in relation to the use of vitamin E in combination with vitamin C is their potential to act synergistically. This may be assisted by the fact that vitamin E is lipid soluble and vitamin C is water-soluble. Alpha-tocopherol is known to sit in the lipid membrane. Ascorbate and alpha-tocopherol, for example, interact at the interface between cell membranes or lipoproteins and water. Ascorbic acid rapidly reduces alpha-tocopherol radicals in membranes to regenerate alpha-tocopherol.
Beta-carotene has strong antioxidant properties and has been shown to be beneficial against selected cancers, cardiovascular diseases, cataracts and age related macular degeneration. Beta-carotene is particularly effective at scavenging peroxyl radicals and is a very potent singlet oxygen quencher at low oxygen tensions. Supplementation of the diet with beta-carotene has been reported to reduce lipid peroxidation.
The food supplement of the first aspect of the invention will optionally contain beta- carotene as a level of from 1 Omg per kilogram body weight to O.OOlmg per kilogram body weight per day, preferably 0.4mg per kilogram body weight to 0.05mg per kilogram body weight per day, more preferably 0.3mg per kilogram body weight or above per day.
The antioxidant vitamins (including sources of such vitamins, such as beta-carotene) of the first aspect of the invention are provided in combination with one or more compounds, which exhibit antioxidant or anti-inflammatory properties. These compounds include eugenol, selenium, carotenoids, flavenoids, phyto-oestrogens, proanthrocyanidins, herbal phenolic compounds or ubiquinone.
The food supplement of the first aspect of the invention optionally provides a source of eugenol. Eugenol is a naturally occurring aromatic hydrocarbon. It is the active ingredient of spices such as cloves (Osmium spp.), garlic and nutmeg. Eugenol has been shown to possess hepatoprotective properties and its administration results in reduced levels of lipid peroxides in vivo. In addition, eugenol has been shown to protect erythrocytes against free radical damage and eugenol exhibits antioxidant properties.
Eugenol is provided at levels of between 15mg per kilogram body weight and O.OOlmg per kilogram body weight per day, preferably at levels of between lmg per kilogram body
weight and O.Olmg per kilogram body weight per day, more preferably O.lmg per kilogram body weight per day or above.
The food supplement of the first aspect of the invention optionally provides selenium. Selenium is a trace element that functions as a co-factor in the body, specifically as a cofactor within antioxidant metalloenzyme systems. For example, selenium is an essential part of the antioxidant selenoenzyme, glutathione peroxidase. Selenium acts as an antioxidant (with activity as a free radical scavenger) and has been shown to act in combination with vitamin E. It has now been shown that glutathione levels in horses with COPD, are reduced. Therefore selenium supplementation is of added benefit.
The food supplement of the first aspect of the invention may provide selenium at a level of from O.OOlmg per kilogram body weight to O.Olmg per kilogram body weight per day, more preferably from 0.006 mg per kilogram body weight to 0.001 mg per kilogram body weight per day, preferably 0.002mg or above per kilogram body weight per day.
The food supplement of the first aspect of the invention optionally comprises one or more carotenoids. The carotenoids are a group of red, orange and yellow pigments predominately found in plant foods, particularly fruit and vegetables, and in the tissues of animals which eat the plants. They are lipophilic compounds. Some carotenoids act as a precursor of vitamin A, . some cannot. This property is unrelated to their antioxidant activity. Carotenoids can act as powerful antioxidants. Carotenoids are absorbed in varying degrees by different animal species. Carotenoids may be classified into two main groups; those based on carotenes and those based on Xanthophylls (which include oxygenated compounds). Common carotenoids include beta-carotene, alpha carotene, lycopene lutein, zeaxanthin and astaxanthin.
The food supplement of the first aspect of the invention optionally contains one or more flavenoids. Flavenoids are found in many plant sources including fruits, vegetables and herbs. They have been reported to have multiple biological effects including their ability to act as antioxidants. Most of the biological roles played by the flavenoids are associated with their transition metal binding capabilities (i.e. iron and copper). Selected flavenoids have been found to have a much higher antioxidant activity than the commonly known
antioxidants such as vitamin C or vitamin E. Examples of flavenoids include quercetin, ellagic acid, myricetin and gossypol.
The food supplement of the first aspect of the invention optionally contains one or more phytoestrogens. Phytoestrogens are naturally occurring compounds found in many plants. They are structurally and functionally similar to oestrodiol or produce oestrogenic effects. Phytoestrogens include lignans, isoflavones, counestans and resorcylic acid lactones. These compounds have been reported to possess antioxidant, anticarcinogenic, bactericidal, anti-viral, anti-inflammatory and antihypertensive activities. Sources of phytoestrogens include soya.
The food supplement of the first aspect of the invention optionally contains one or more of proanthrocyanidins. Proanthrocyanidins are potent antioxidant compounds, which in addition to protecting tissue from oxidative injuries can prevent cardiovascular diseases by counteracting the effects of high cholesterol.
The food supplement of the first aspect of the invention optionally provides a source of herbal phenolic compounds. Herbal phenolic compounds are naturally occurring compounds found in plants, especially herbs. The compounds are aromatic hydrocarbons, which exhibit antioxidant properties.
The food supplement of the first aspect of the invention optionally contains ubiquinone (also known as co-enzyme Q). Ubiquinone is a co-enzyme that is involved in the formation of ATP in the body. The co-enzyme is a quinone derivative that has anti-oxidant activity. Natural sources of ubiquinone include green leafy vegetables. Ubiquinone is believed to be non-toxic. It is thought that the coenzyme interacts with vitamin E to regenerates its antioxidant form, thus the administration of vitamin E and ubiquinone may provide a synergistic effect. Ubiquinone is believed to stabilise mitochondrial membranes and to help detoxify oxygen free radicals.
Ubiquinone is provided in this aspect of the invention at a level of between 20mg per kilogram body weight and 0.05mg per kilogram bodyweight per day, more preferably at a
level of between 2mg per kilogram bodyweight and 0.3mg per kilogram bodyweight per day and most preferably of 0.5mg or above per kilogram bodyweight per day
The food supplement of the first aspect of the invention may additionally one or more B vitamins. Preferably, the B vitamins include one or more selected from vitamin B-2
(riboflavin), vitamin B-6 (pyridoxine), vitamin B-l (thiamine), vitamin B-12 (cobalamin), vitamin B-3 (niacin), pantotheic acid and folate.
Nitamin B-l (thiamine) is involved in metabolism. It aids the digestion of carbohydrates allowing the generation of energy. Thiamine is essential for the normal functioning of the nervous system, muscles and heart.
Vitamin B-2 (riboflavin) is necessary for carbohydrate, fat and protein metabolism and maintains cell respiration. It aids in the formation of antibodies and red blood cells. It is necessary for the maintenance of good vision, skin, hair and nails and alleviates eye fatigue.
Nitamin B-6 (pyridoxine) is necessary for the synthesis and breakdown of amino acids and aids in fat and carbohydrate metabolism. It maintains the central nervous system and aids in the formation of antibodies. Nitamin B-6 has been shown to promote healthy skin and reduce muscle spasms, leg cramps, hand numbness, nausea and stiffness of the hands.
Folate is necessary for both DΝA and RΝA synthesis. It is essential to the formation of red blood cells and aids amino acid metabolism. Folate is preferably provided at a level of between 0.5 mg per kilogram body weight to O.OOlmg per kilogram body weight per day more preferably a level of between 0.25 mg per kilogram body weight to 0.01 mg per kilogram body weight per day.
The food supplement of the first aspect of the invention can optionally include trace elements such as iron, calcium, magnesium, copper, zinc and manganese. Preferably, the food supplement of the first aspect of the invention optionally includes copper and zinc.
Copper and zinc form an integral part of the antioxidant metalloenzyme Cu-Zn-superoxide
dismutase, which converts superoxide free radical to hydrogen peroxide. This conversion represents the first line of defence against activated oxygen species.
The components of the first aspect of the invention including the antioxidant vitamins and the antioxidant compounds can be provided by a natural source, a synthetic source or a mixture of one or more natural sources and one or more synthetic sources. In a preferred aspect of the invention, a portion of the antioxidant vitamin is provided by a synthetic source and a portion of the antioxidant vitamin is provided by a natural source.
A synthetic source for the purpose of this invention provides the component (for example, the antioxidant vitamin) substantially free of any other material. The synthetic source of the component is more than 70% pure, preferably more than 85% pure, more preferably more than 95% pure. The synthetic source can be any material which has been prepared from available starting materials by a series of biochemical or chemical reactions. The product of these reactions can then be partially or fully purified. In addition, the component can be isolated from a natural source. The required component is removed from the other components of the natural source and purified until only the required component is present. The synthetic source can be provided alone or can be admixed with other components including other molecules with antioxidant properties, pharmaceutically acceptable excipients, stabilising agents, anti-caking agents, emulsifiers, etc. The synthetic source can be provided in combination with a carrier such as silica. The structure of the synthetic product may correspond exactly to the structure of the component in nature or it can be an analogue of that structure. The synthetic product may be provided in a form which can be modified in the body to produce one or more active components (e.g. by the hydrolysis of an ester, etc).
The antioxidant vitamins can be provided by a synthetic source. The structure of the synthetic product may correspond exactly to the structure of the vitamin C, vitamin E or beta-carotene as found in nature or it can be an analogue of those structures. The synthetic compound can be provided as a pure form of vitamin C, vitamin E or beta-carotene or can provide vitamin C, vitamin E or beta-carotene in combination with a pharmaceutically acceptable excipient, a stabilising agent, or any other mixing material. The synthetic
substrate can be in the form of a powder, granule, pellet, tablet, capsule, liquid or semi solid form.
Nitamin C for the present invention can be obtained from a number of synthetic sources including crystalline ascorbic acid (optionally pure), ethylcellulose coated ascorbic acid, calcium phosphate salts of ascorbic acid, ascorbyl pahnitate, stabilised ascorbyl palmitate, ascorbic acid-2-monophosphate salt or ascorbyl-2-monophosphate with small traces of the disphosphate salt and traces of the triphophate salt or calcium phosphate (Stay-C®). Preferably, the vitamin C is provided as Stay-C® or ascorbyl palmitate.
Nitamin E for the present invention can be provided by a number of synthetic sources. Preferably the Nitamin E is provided as DL-alpha-tocopherol or DL-alpha-tocopherol acetate.
A natural source for the purposes of this invention provides the required component in combination with one or more other compounds. Preferably, the required component is provided within its naturally occurring matrix. For example, where vitamin C is provided by unprocessed broccoli, the vitamin C is provided in combination with carbohydrates, fibre, proteins, lipids, chlorophyll and other plant materials. The natural source of the required component can be an extract or a derivative of a natural source (for example, a plant, animal or mineral). The isolated or partially isolated material may then be partially purified by one or more purification steps. Alternatively, the component may be provided as part of a raw and unprocessed material. The raw unprocessed material may be cooked and/or dried. Furthermore, the processed, partially processed or unprocessed material can be reconstituted in the form of a solid, semi-solid or liquid.
The antioxidant vitamins can be provided by a natural source. Nitamin C, vitamin E or beta-carotene can be provided by a natural source containing vitamin C, vitamin E and beta-carotene. Alternatively, each of vitamin C, vitamin E or beta-carotene can be provided by a different natural source. In addition, two or more of vitamin C, vitamin E or beta-carotene can be provided by a particular natural source.
The antioxidant vitamins can be provided by a natural source, preferably by plant material. For the purposes of this invention, the plant material can come from any part of a plant (for example, the leaf, root, stem, bark, bulb, fruit, flower or seed) and can be any combination of such parts. The plant material can be unprocessed, semi-processed or processed and can be provided as a solid, an extract, an oil, a powder, dried or in solution.
Preferably, beta-carotene is provided by one or more of maize meal, broccoli, spinach, carrots, squash, tomato meal, red palm oil, tomato powder or tomato pomace/pulp. A preferred source of vitamin E is extracted tocopherols. The tocopherols can be from red palm oil or grape seed oil. In a preferred embodiment of the invention, the natural source of vitamin E and beta-carotene is red palm oil.
More preferably, the natural source of the antioxidant vitamins is a member of the Brassica (cabbage) family or a leafy green vegetable such as spinach or a combination of both. The Brassica family, for the present invention includes broccoli, cabbage (including savoy cabbage, red cabbage and Chinese cabbage), cauliflower, brussel sprouts, kale (including curly kale) and chard. More preferably, the natural source is broccoli, curly kale and/or spinach.
Broccoli is a source of vitamin A, vitamin B-2, vitamin B-6, folate, vitamin C, calcium, potassium and selenium. For the purposes of this invention, the broccoli can be raw, semi- cooked or cooked. Methods of cooking broccoli include baking, steaming and boiling. The broccoli may be dried or partially dried. Any form of broccoli for example, raw, semi- cooked or cooked can be dried. Preferred forms of dried broccoli include those containing between 0 and 40% w/w water, or between 0 and 10 %, or between 0 and 5%. All preferred features described above for broccoli can also be applied to other members of the Brassica family.
The addition of members of the Brassica family to the food supplement of the first aspect of the invention will provide additional antioxidant effects. The Brassica family contains important sulphur-containing phytochemicals, including glucosinolates and S-methyl- cysteine sulphoxide. The phytochemicals have antioxidant capacity and show beneficial effects as anti-cancer agents.
One embodiment of the invention involves a food supplement containing a level of dried broccoli from 5mg to 50mg per kilogram body weight per day, preferably the food supplement contains a level of 20mg per kilogram body weight per day or above of dried broccoli or an equivalent amount of a semi-dried or fully hydrated form of broccoli.
Green leafy vegetables for the present invention include spinach (Spinacia oleracea). Spinach is high in fibre and contains vitamin A, vitamin B-2, folate, vitamin B-6, vitamin C, vitamin E, potassium and zinc. For the purposes of this invention, the spinach can be raw or cooked. Methods of cooking spinach include baking, steaming and boiling. The spinach can further be dried. Either raw or cooked spinach can be dried. Preferred forms of dried spinach include those containing between 0 and 40% w/w water, or between 0 and 10 %, or between 0 and 5%.
One embodiment of the invention involves a food supplement containing a level of dried spinach from 5mg to 50mg per kilogram body weight per day, preferably the food supplement contains a level of 20mg per kilogram body weight per day or above of dried spinach or an equivalent amount of a semi-dried or fully hydrated form of spinach.
The food supplement of the first aspect of the invention provides the antioxidant vitamins in combination with one or more of eugenol, selenium, a carotenoid, a flavenoid, a phyto- estrogen, a proanthrocyanidin, a herbal phenolic compound or ubiquinone. The antioxidant compounds listed above can be provided by a natural source, a synthetic source or a mixture- of one or more natural sources and one or more synthetic sources. In a preferred aspect of the invention, a portion of the antioxidant compound is provided by a natural source and a portion of the antioxidant compound is provided by a synthetic source. Definitions of the natural and synthetic sources as discussed for the antioxidant vitamins also apply to the antioxidant compounds.
The source of eugenol is not limiting and can include natural and synthetic sources. For the first aspect of the invention, eugenol may be provided by one or more of garlic, cloves, or nutmeg. Where eugenol is provided by garlic, it can be provided by the bulb or the shoot or a combination of the bulb and the shoot.
Garlic is a member of the Allium family. For the purposes of the present invention, garlic can be replaced by any member of the Allium family including onions, shallots, chives and leeks. Garlic has a number of beneficial characteristics. It is reported to be a hypotensive, diuretic, vasodilator, hypoglycaemic, anticarcinogenic agent, antibacterial agent, antiviral agent antiinflammatory agent and expectorant. It is also reputed to protect against strokes, coronary thrombosis, atherosclerosis and platelet aggregation.
The active agents of garlic are a family of sulphur containing compounds, the thioallyl compounds. These include alliin, allicin, alliinase, ajoene and vinyldithiins. The presence of these organosulphur compounds accounts for garlic's antioxidant properties.
Garlic according to the first aspect of the invention may be in any form. It may be dried, fresh, crushed, in solution, in oil, as a powder, liquid (either as a solution or as an oil) or semi-solid.
Dried garlic is provided at levels of between 30 mg per kilogram body weight and 1 mg per kilogram body weight per day, preferably at levels of between 20mg per kilogram body weight and 2mg per kilogram bodyweight per day, more preferably at levels of 2mg per kilogram body weight per day and above or an equivalent amount of a semi-dried or fully hydrated form of garlic.
An alternative source of eugenol for the first aspect of the invention is nutmeg. Nutmegs are widely used in cooking due to their strong bitter warm aromatic taste. They contain eugenol, lignin, stearin, volatile oil, starch, gum and am acid substance. Oil of nutmeg is used medicinally to conceal the taste of various drugs and as a local stimulant to the gastrointestinal tract.
Nutmeg according to the first aspect of the invention may be in any form. It may be dried, fresh, crushed, in solution, in oil, as a powder, liquid (either as a solution or as an oil) or semi-solid.
Dried nutmeg is provided at levels of between 30 mg per kilogram body weight and 1 mg per kilogram body weight per day, preferably at levels of between 20mg per kilogram body weight and 2mg per kilogram bodyweight per day, more preferably at levels of 2mg per kilogram body weight per day and above or an equivalent amount of a semi-dried or fully hydrated form of nutmeg.
The first aspect of the invention may contain one or more flavenoids from natural and synthetic sources. The source of the flavenoid is not limiting. More preferably, the natural source of flavenoids is one or more of rosemary and liquorice.
Rosemary is a widely used culinary herb. The plant contains tannic acid, resin and a volatile oil, which contains Borneol, bornyl acetate and other esters and a camphor derivative. Oil of rosemary is used as a tonic, astringent, diaphoretic and stimulant.
Dried rosemary is provided at levels of between 30 mg per kilogram body weight and 1 mg per kilogram body weight per day, preferably at levels of between 20mg per kilogram body weight and 2mg per kilogram bodyweight per day, more preferably at levels of 2mg per kilogram body weight per day and above or an equivalent amount of a semi-dried or fully hydrated form of rosemary.
Liquorice has been shown to contain active sponins including glycvrrhizin. These compounds have been reported to have liver-protective effects through their anti-free radical properties. Glycyrrhizin is converted into its aglycone by intestinal flora. Flavonoid aglycones are very bio-available.
For the purposes of this invention the liquorice may be dried or partially dried, in the form of a powder, in oil, liquid (either as a solution or as an oil), crushed, an extract, fresh or semi-solid. Preferred forms of dried liquorice include those containing between 0 and 40% w/w water or between 0 and 10% or between 0 and 5%. Dried liquorice is preferably provided at a level of 5mg per kilogram body weight to 0.05mg per kilogram bodyweight per day more preferably lmg per kilogram bodyweight per day or above.
The first aspect of the invention relates to a food supplement which may contain herbal phenolic compounds. The source of the herbal phenolic compounds is not limiting and can include natural and synthetic sources. The herbal phenolic compounds can be provided by a natural source such as a plant, more preferably a herb plant. The phenolic compounds can be provided by one herb or by a mixture of herbs, for example, one or more of rosemary, nutmeg, oregano, basil and coriander. For the purposes of this invention, any part of the herb plant can be used (for example, leaf, stem, bark, bulb, root, fruit, flower or seed). The herb material can be dried, semi-dried, fresh, crushed, in oil, in solution as a powder, liquid (as a solution or as an oil) or semi-solid.
Alternatively, the herbal phenolic compound is provided as an extract from a plant. The phenolic compound can be extracted and partially or fully purified from the herb.
Preferably the phenolic compounds are obtained from rosemary.
Several phenolic compounds extracted from Rosemary (and related family members such as oregano) have exhibited antioxidant effects. Phenolics from rosemary include carnosol, rosemanol, carnosic acid and rosemaridiphenol. These phenolic compounds may act as antioxidants, inhibit carcinogenesis or act as anti-inflammatory agents.
Rosemary according to the first aspect of the invention may be in any form. It may be dried, fresh, crushed, in solution, in oil, as a powder, liquid (either as a solution or as an oil) or semi-solid.
The first aspect of the invention relates to a food supplement, which may contain a further source of carotenoids. The source of carotenoids is not limiting and can include natural and synthetic sources. In particular, the preferred source is a natural source and includes; marigold meal and lucerne meal (sources of lutein); maize meal, tomato meal, red palm oil, tomato powder, tomato pomace/pulp (sources of beta-carotene and lycopene). Sources include oils high in carotenoid levels and pure manufactured carotenoids such as lutein, violaxanthin, cryptoxanthin, bixin, zeaxanthin, apo-EE (Apo-8-carotenic acid ethyl ester), canthaxanthin, citranaxanthin, achinenone, lycopene and capsanthin. More preferably, the source of the carotenoids is red palm oil.
The first aspect of the invention may optionally comprise proanthrocyanidins. The proanthrocyanidins of the present invention can be provided by natural or synthetic sources. The source of the proanthrocyanidins is not limiting. Preferably, the proanthrocyanidins are provided by grape seed oil.
The first aspect of the invention may optionally comprise ubiquinone. The source of ubiquinone is not limiting and can include natural or synthetic sources. Natural sources of ubiquinone include green leafy vegetables including spinach and members of the Brassica family.
The first aspect of the invention may further comprise a source of selenium, wherein the selenium is provided by a synthetic or a natural source. The source of the selenium is not limiting. Natural sources of selenium include members of the Brassica family, more preferably broccoli. An alternative natural source of selenium is selenium yeast. Synthetic sources of selenium include any salt or complex of selenium including any organoselenium molecules. Preferably, selenium is provided as sodium selenate.
The food supplement of the first aspect of the invention optionally contains B-vitamins including folate. The B-vitamins can be provided by natural or synthetic sources.
Definitions of natural and synthetic sources discussed in relation to the antioxidant vitamins also apply to this aspect of the invention. Natural sources of the B vitamins include Brewers yeast.
Brewers yeast is provided in the food supplement in this aspect of the invention at a level of between 50mg per kilogram body weight and 5mg per kilogram body weight per day, preferably at a level of 20mg per kilogram body weight per day or above.
The B vitamins may alternatively be provided by plant material. The B vitamins may be provided by a member of the Brassica family (broccoli, cabbage (including savoy cabbage, red cabbage and Chinese cabbage), cauliflower, brussel sprouts, kale (including curly kale) and chard), more preferably broccoli, or a green leafy vegetable such as spinach. The plant material can be in any form as discussed above.
The food supplement of the first aspect of the invention can further comprise trace elements such as calcium, magnesium, copper, zinc and manganese. The trace elements can be provided by a synthetic or a natural source. Natural sources of such elements (for example potassium and calcium) include members of the Brassica family, more preferably broccoli. Zinc and potassium can be provided by green leafy vegetables such as spinach. Synthetic sources of the trace elements include any salt or complex of the metal including any organometallic molecules. Preferably zinc, copper, magnesium and manganese are provided as the chloride, carbonate or sulphate salts or as the organic chelate.
The food supplement of the first aspect of the invention can additionally contain ingredients, which enable the food supplement to be formulated in a particular form. For example, the food supplement can contain molasses or a molasses/oil mixture for example cane molasses with approximately 6% or above oil such as Molglo (eg. to bind the ingredients together or as a palatability agent) or, oat feed, wheat feed or another suitable filler ingredient (as a filler ingredient). The food supplement may also contain a fibre source such as grasses, sugar beet, soya hulls and oats, a fat source such as corn oil, soya oil, processed canola oil, coconut oil, palm oil or sunflower oil and/or a starch source such as cereals (eg. corn, barley, oats). Thus, the food supplement may be a food.
The food supplement of the first aspect of the invention can contain a combination of the components discussed above.
hi a more preferred embodiment of the first aspect of the invention, the food supplement comprises:
a natural source of carotenoids including beta-carotene (for example red palm oil), a natural source of phyto-oestrogens (for example one or more of broccoli and spinach), a natural source of vitamin B including folate (for example, one or more of broccoli or spinach), a synthetic source of folate,
a natural source of vitamin C (for example, one or more of broccoli or spinach), a synthetic source of vitamin C (for example Stay-C) a natural source of vitamin E (for example red palm oil), a synthetic source of vitamin E (for example, alpha-tocopherol), a natural source of eugenol (for example one or more of garlic or nutmeg), a natural source of flavenoids (for example one or more of rosemary or liquorice), a synthetic source of selenium (for example sodium selenate), a natural source of proanthrociadins (for example grape seed oil), a natural source of herbal phenolic compounds (for example rosemary).
In a most preferred embodiment of the first aspect of the invention, the food supplement comprises the following ingredients.
Table 1
Alternatively the food supplement comprises the following ingredients.
Table 2
The food supplement of the first aspect of the invention can be provided in varying quantities per day. For example, for an approximately 500kg horse, the food supplement can be provided in quantities of between 4kg per day and lOOg per day. Preferably, the food supplement would be provided in quantities of 750g to 150g per day, more preferably 200g or above. The figures are pro rata for differently sized horses.
For example, the food supplement can be fed in quantities of between SOOg and 20g per 100kg bodyweight per day, preferably in quantities of 150g to 30g per 100kg bodyweight per day, more preferably 50g per 100kg bodyweight per day or above.
Preferred quantities of the food supplement for a horse of a given bodyweight are set out below.
Table 3
The above tables 1 and 2 indicate the composition of a food supplement which would be provided in an amount of 250g per day and would be fed to a horse of approximately 500kg bodyweight. It should be appreciated that if the total amount of supplement was to be increased, this would be achieved by increasing the amount of filler ingredients,
binders or fibre source while maintaining the absolute amounts of the other components. Conversely, if the total amount of food supplement was to be decreased, the amount of filler ingredients, binders or fibre source would be reduced, whilst maintaining the absolute amounts of the other components.
The three ingredients, oat feed, maize gluten and soya bean hulls will together typically provide between 20-91% of a supplement of 250g or higher. However, for a low volume supplement the oat feed, maize gluten and soya bean hulls may together be provided at levels of approximately 20% or less of the supplement. For example, for a supplement of approximately lOOg per day, the total amount of oat feed, maize gluten and soya bean hulls may be approximately 6-10% of the supplement.
The food supplement of the first aspect of the invention can be solid, semi-solid or liquid for example the food supplement could be in the form of a powder, a pellet or a drink. The food supplement can be added to the food or administered prior to or after feeding.
Typically, the supplement will be administered together with the standard foodstuff used. The mixing may occur when the foodstuff is prepared or packaged or may occur when the foodstuff is provided to the animal. The supplement may alternatively be supplied as a topping to the foodstuff. The food supplement can be in the form of a food snack or drink (for example, snack bars, biscuits, and sweet products). The drink may be aqueous or oil based.
The food supplement of the first aspect of the invention can be prepared using convention techniques.
In one embodiment of the first aspect of the invention, the food supplement is provided as a pellet. The ingredients of the food supplement are mixed together and the product mix is passed through a die plate containing several holes of a nominated size (for example from
4 mm to 16 mm, more preferably from 4 mm to 9 mm). Minimal heat is applied to the mixture prior to its entering the mixer to raise the temperature of the mixture to approximately 50°C. Temperatures of 95°C have been used to raise the temperature of the mixture to the required temperature.
The food supplement can be provided as an extruded pellet. In this process, the mixture enters the extruder where it is heated. By forcing the product along the barrel of the extruder through a series of precision restrictors, the product is exposed to high temperatures and high pressures. The product emerges from the extruder through a shaped die where it expands as the pressure immediately falls to room pressure. The extruded material is then cut to the required length.
According to the second aspect of the invention there is provided a food supplement of the first aspect of the invention for use in achieving a health benefit. The health benefits may be for unhealthy or healthy animals. The use can be termed as "medicine" although this term does not necessarily mean that the food supplement is a licensed medicament subject to regulatory authorisation requirements. Thus the food supplement may be used in "medicine". The food supplement may be used in aiding the prevention or treatment of oxidative damage. The food supplement may be used in aiding the prevention or treatment of an animal suffering from respiratory disease, for example where that disease involves inflammation of the respiratory tract. The food supplement of the first aspect of the invention may be for the simultaneous, sequential or separate use in aiding the treatment of an animal suffering from respiratory disease.
The food supplement of the first aspect is provided to support the health of an animal. The food supplement provides antioxidants which are important in maintaining or improving the natural defences of the lung. Thus, the food supplement can be used to maintain the optimum health of an animal. Where an animal is suffering from a respiratory disease, the food supplement can be used in combination with one or more conventional therapies. Administration of the foodstuff may result in an improvement of the symptoms or a slowing of the progression of respiratory disease.
For the purposes of this invention, the terms "aid" and "aiding" mean to decrease or alleviate the symptoms suffered by an animal especially the symptoms of a respiratory disease suffered by a horse. This aid may allow the reliance on a drug therapy to be reduced. Alternatively the animal may exhibit less symptoms or the severity of the symptoms may be reduced. The animal may exhibit an improved level of fitness or an improved level of well being.
The food supplement of the first aspect of the invention may be used in aiding the treatment of an animal suffering from chronic obstructive pulmonary disease. In particular the food supplement is used where the animal is equine. Equine animals for the purposes of this invention include horses, ponies, camels and donkeys. Other mammals include for example human, feline or canine.
Without limiting the present invention, there is some evidence that reactive oxygen species may have a role in respiratory disease. Work has indicated that horses suffering from recurrent airway obstruction demonstrate oxidative stress. The food supplement of the invention has provided a cocktail of antioxidant compounds derived from natural sources which decreases the level of inflammation in horses suffering from COPD. Reactive oxygen species have also been implicated in asthma and related conditions.
Administration of the food supplement of the first aspect of the invention to an animal will provide an increased level of compounds with antioxidant activity thus reducing oxidative stress to the lung. This will be particularly beneficial where an animal has been or will be or is subjected to an increase in exercise (for example before a competition) or where an animal is exposed to free radicals due to pollution. The food supplement may help in maintaining the healthy respiratory system of a horse by supporting or improving the natural defences of the lung.
It is understood that animals will already be consuming some level of antioxidants through their normal diet. The food supplement of the first aspect of the invention can be used to increase the level of antioxidants in animals such as horses, in particular for those in need
(for example those suffering from respiratory diseases or undergoing exercise). The food supplement is administered to healthy horses in order to supplement their levels of antioxidant and to help protect them against oxidative injury, hi addition, the food supplement can be administered to those animals whose diet is nutritionally deficient in order to provide antioxidant compounds, which are not provided by the diet.
As previously discussed, treatment of COPD in horses involves preventing further attacks by environmental management or the use of prescription medication which can be costly
and involves the risk of unwanted side effects. Administration of the food supplement of the first aspect of the invention can reduce the need for prescription medication thereby decreasing the risk of side effects to that medication.
The second aspect of the invention provides a food supplement, which provides an effective prophylaxis or adjunct treatment for COPD in horses. The food supplement may be manufactured from natural sources and provides a more natural treatment for this condition.
A further aspect of the invention provides a food supplement, which provides a contribution to the effective prophylaxis or treatment of asthma. Administration of the food supplement of the invention to an individual suffering from asthma will decrease lung inflammation thus decreasing the severity of the symptoms.
In a third aspect of the invention, there is provided a food supplement containing vitamin C for use in medicine, h particular, the third aspect of the invention is for use as described according to the second aspect of the invention. It may be for use in the natural defence of the lungs in a horse (health defence), and for use in aiding in the prevention or the treatment of respiratory disorders in horses. In particular, the food supplement is for use in aiding the prevention or treatment of horses suffering from COPD.
All preferred features of the first aspect of the invention also apply to the second and third aspects of the invention, including levels and other details of vitamin C and other components. The food supplement according to the third aspect of the invention may comprise" selenium, in accordance with the details and preferred features of the first and second aspects of the invention.
A fourth aspect of the invention provides the use of the food supplement of the first aspect of the invention for the manufacture of a food stuff to aid in the prevention or treatment oxidative damage. The oxidative damage may be concentrated in the respiratory tract.
The fourth aspect of the current invention provides the use of the food supplement of the first aspect of the invention for the manufacture of a food stuff for aiding the prevention or
treatment of an animal suffering from a respiratory disease. The respiratory disease may involve inflammation of the respiratory tract.
All preferred features of the first, second and third aspects of the invention also apply to the fourth aspect of the invention.
A fifth aspect of the current invention involves a method of contributing to the prophylaxis or treatment of an animal susceptible to or suffering from oxidative damage. The fifth aspect of the invention also relates to a method of contributing to the prophylaxis or treatment of an animal susceptible to or suffering from a respiratory disease. In particular this relates to a method of treatment where the respiratory disease involves ah inflammation of the respiratory tract. However, it is clear that the method may have more general effects throughout the body. In each case, the method comprises administering to the animal a food supplement of the first aspect of the invention. The animal is preferably in need of the prophylaxis or treatment.
All preferred embodiments of the first, second, third and fourth aspects of the invention also apply to the fifth aspect of the invention.
The sixth aspect of the invention provides a food stuff comprising a food supplement of the first aspect of the invention.
The food stuff can be solid, semi-solid or liquid. It is preferably packaged. The packaging may be metal, plastic, paper or card. The amount of moisture in any product may influence the type of packaging, which can be used or is required.
The food stuff according to the present invention encompasses any product, which an animal consumes in its diet. Thus, the invention covers standard food products as well as food snacks (for example, snack bars, biscuits and sweet products).
The food stuff according to the sixth aspect of the invention may be for use in medicine. The food stuff may be used to aid in the prevention or treatment of oxidative damage. The oxidative damage of this aspect of the invention may be caused by exposure to pollutants,
UV light or radiation. The oxidative damage may be concentrated in the respiratory tract. The food stuff may be used to aid in the prevention or treatment of an animal suffering from respiratory disease. The food stuff may be used where the respiratory disease is chronic obstructive pulmonary disorder.
The food stuff of the sixth aspect of the invention can be prepared using conventional techniques. In particular, one or more components of the food supplement are mixed with a conventional food stuff. The food stuff may then be cooked or chilled and further substances can be added.
The foodstuff of the sixth aspect of the invention maybe a complete food (i.e. containing all necessary nutrients), a complementary food (which is fed with forage, salt and water), a semi-complementary food (which provides a portion of the necessary nutrients) or a supplementary food (which contains specified amounts of one or more nutrients).
All preferred embodiments of the first, second, third, fourth and fifth aspects of the invention also apply to the sixth aspect.
A seventh aspect of the invention provides the food supplement of the first aspect of the invention or food stuff of the sixth aspect of the invention for administration to an animal as an ergogenic aid. Preferably, for this aspect of the invention, the animal is equine.
An ergogenic aid is any factor, which can increase or improve work production. This could be an increase in speed or endurance or strength.
The seventh aspect of the invention further provides a method of improving or increasing the work production of an animal comprising administering the ergogenic aid as a food supplement of the first aspect of the invention or as a food stuff of the sixth aspect of the invention.
The invention further provides a food supplement of the first aspect of the invention or a food stuff of the sixth aspect of the invention for use in the preparation of an ergogenic aid.
Without limiting the invention it is proposed that the presence of anti-oxidants (vitamin C, vitamin E, selenium, zinc or ubiquinone) in the food supplement acts as a defence against oxidant-induced membrane injury in tissue, hi particular it is proposed that vitamin E acts as the defence mechanism while vitamin C regenerates the membrane bound vitamin E. Vitamin A and beta-carotene accumulates in tissue membranes and it is believed that these free radical scavengers will react directly with the peroxyl free radicals generated during exercise and serve as additional lipid soluble anti-oxidants. And/or improved oxygen transport due to reduced inflammation within the lung may contribute to any ergogenic effect.
Preferred features of the first, second, third, fourth, fifth and sixth aspects of the invention will also apply to the seventh aspect.
The invention will now be described with reference to the following non limiting examples.
Example 1
Six horses suffering from COPD (3 mares and 3 geldings 16.2 +/- 2.4 yrs; 515 +/- 80kg) were chosen for this study. The horses were in clinical remission from COPD and were fed and managed in such a way to limit respiratory challenge. The horses were trained to run on a high speed treadmill for 6 weeks prior to the study. At the end of this adaptation period the horses showed similar lactate and heart rate responses to an exercise bout.
The horses were fed the same basal diet (normal diet for all the research horses ) for a 6 week adaptation period whilst they were being trained to exercise on the high speed treadmill.
25 Og of either the food supplement (A) or a oat hull pellet (B) was fed, in addition to the basal diet, during the feeding periods. The basal diet only was fed during the washout period. Those horses which received supplement A first were then, after the washout period, switched to B and vice versa. The same forage was used throughout.
Evaluations were carried out at rest and during exercise at the start of the study; at the end of the first and second feeding periods and after the washout period.
Table 4 - Food supplement A
The above ranges were used in a 250g supplement fed to a horse of approximately 500kg body weight.
Summary of study
Pre study evaluation
4 weeks on diet A or diet B
Evaluation at end diet A or B
4 weeks washout period on original pre-study diet
I '
Evaluation at end of washout
I Crossover - 4 weeks on alternative diet
I
Evaluation at end of diet B or A
A number of evaluations were carried out on the horses at rest, including: Haematology
Blood samples for Vitamin E and markers of systemic oxidative stress, Uric acid, MDA, isoprostanes, Glutathione (GSH, GSSG, TGSH, GRR), Vitamin E, total antioxidant status.
Arterial blood gases, Mechanics of breathing, Endoscopy and scoring of airway inflammation, Bronchoalveloar lavage for cytology and pulmonary markers Uric acid; isoprostanes; glutathione (in pulmonary epithelial lining fluid).
2. 24 hrs later - Exercise test on a high speed Treadmill
5 mins walk - I
5 mins trot
2 mins canter at 8 m/s
1 8 mins trot
-I
2 mins canter at 9 m/s
8 mins trot 2 mins canter at 10 m s , 10 mins walk
Walk and trot at 0% slope - canters all at 4%
Blood samples were taken at various points during and after the study via a jugular catheter for lactate, uric acid and total antioxidant status.
Heart rate was monitored consistently throughout the study.
Results
Table 5 - Inflammatory score of the airways
A significant improvement in horses fed on food supplement A compared with oat hull pellet B was observed. This effect was observed in the inflammation of the airways, oedema of the bronchial carina and hyperaemia of the airways.
Table 6 - Uric acid production post exercise
Horses fed on food supplement A show a lower degree of uric acid production post exercise than the horses fed on the oat hull pellet B. Uric acid is a breakdown product of ADP. During intense exercise, the ADP accumulates triggering the formation of AMP. Further metabolism of AMP leads ultimately to uric acid which can be detected in the plasma of horses. The accumulation of such end products as uric acid are associated with the onset of fatigue.
Heart Rate
Horses fed on food supplement A showed a significantly reduced heart rate after the third gallop of the exercise treatment compared to horses fed on the oat hull pellet B.
A further study was carried out to investigate the effect of food supplement A. An additional two horses were added to the study and a more complete experimental protocol and results are provided below.
Example lb
Eight horses (5 geldings, 3 mares, aged of 17.0 ± 3.1 years, 513 ± 63 kg bodyweight, mean ± standard deviation (SD)) with a history of COPD were used in this study. All COPD- affected horses were in clinical remission after a two month period on pasture and were selected on base of a clinical examination and routine PFTs. The horses were maintained in clinical remission by bedding them on cardboard litter and feeding them grass silage. They did not receive any medical treatment during the study, which was approved by the Animal Ethics Committee of the University of Liege.
All horses underwent six weeks of controlled conditioning (3 times/week) on a high-speed treadmill (Equispeed, Versailles, Michigan, USA) and were kept by individually adapted training in a stable fitness throughout the study.
After a six weeks period of treadmill exercise conditioning, the horses were randomly divided into two groups of four horses each. Group I was supplemented with food supplement A for four weeks, whilst group II was fed pellet B.
Two hundred fifty gram of either food supplement A or pellet B were fed once daily with one kg of wheat concentrate (molassed oats, pressed corn and pellets). The ingestion of the supplements was systematically verified.
After a wash-out period of four weeks, the treatments were inverted, i.e. group I was fed pellet B and group II was fed food supplement A for further four weeks. The effects of food supplement A and pellet B treatment on pulmonary function and oxidant stress were assessed on two consecutive days before and after each treatment period. On Day 1 (Rest : R), PFTs were performed, followed by blood samplings and BAL for analyses of both systemic and pulmonary uric acid, glutathione and 8-epi-PGF2α. A differential cell count was performed on BAL fluid. On Day 2, twenty-two hours after the first BAL, the horses performed a SET on a treadmill for fifty minutes. Venous blood was sampled for analysis of uric acid, glutathione and 8-epi-PGF2α at peak-exercise (Emax), and fifteen (E15) and sixty (E60) minutes after the end of the SET. Airway endoscopy followed by
Bronchoalveolar lavage (BAL) was performed immediately after last blood sampling (E60) and BAL uric acid, glutathione and 8-epi-PGF2α were analysed. BAL was randomly performed in one lung side on Day 1 and in the other 24 hours later on Day 2.
Pulmonary Function Tests
Each horse underwent routine PFTs prior to admittance to the study (preliminary PFTs) and on Day 1 of the tests. The ventilatory mechanics measurement and the arterial blood gas tension analysis were systematically performed between 9:00 h and 10:00 h in order to reduce the possible influence of circadian rhythm of pulmonary parameters.
Ventilatory mechanics were measured for two minutes when the horse was breathing normally at rest. It required simultaneous pleural pressure and respiratory airflow measurements, hitrapleural pressure was measured by means of an oesophageal balloon catheter made from a condom sealed over the end of a polyethylene catheter (4 mm inner diameter, 6 mm outer diameter, 220 cm long, VEL, Leuven, Belgium) positioned with its tip in the middle thoracic oesophagus and connected to a pressure transducer (Valydine Ml-45, Valydine Engineering, Northridge, CA, USA). An airtight facemask covered
horse's nostrils and mouth. The mask was shaped in order to minimise dead space and to avoid nasal compression. A Fleisch pneumotachograph Nr.4 mounted on the facemask was coupled by two identical catheters (4 mm inner diameter, 6 mm outer diameter, 220 cm long, VEL, Leuven, Belgium) to a differential pressure transducer (Valydine DP45-18, Valydine Engineering, Northridge, CA, USA). Respiratory airflow and oesophageal pressure were simultaneously measured and dynamic compliance (CDyn), total pulmonary resistance (R ) and maximal pleural pressure changes (Ma ΔPpl) were continuously calculated on a breath-by-breath basis and recorded by a computerised system (Po-Ne- Mah, Gould Instrument Systems, Valley View, OH, USA). Volume and pressure calibrations were performed with a 2 L pump (Medisoft, Dinant, Belgium) and a water manometer, respectively.
Arterial blood was withdrawn anaerobically from the Arteria carotis communis and analysed, after correction for body temperature, for partial pressure in oxygen (PaO ) and carbon dioxide (PaCO2) (AVL 995, VEL, Leuven, Belgium).
No significant differences in CDyn, R , MaxPpl, PaO2 and PaCO2 between protocols were found suggesting no adverse effect of feeding supplement A.
Blood sampling and processing
Venous blood samples were collected on heparin tubes by jugular puncture on Day 1 and via a jugular catheter placed immediately before the SET on Day 2. All samples were immediately cooled on ice and processed within two minutes after collection. After centrifugation (10 min at 4°C, 900 x g) plasma was aliquoted into 1 ml samples and snap frozen in liquid nitrogen for urea, uric acid and 8-epi-PGF2α determinations. Centrifuged packed blood cells (0.5 mL) were carefully mixed with EDTA (2 mmol in 0.5 mL H2O), snap frozen and stored in liquid nitrogen for glutathione analysis.
Airway endoscopy and bronchoalveolar lavage procedure
An endoscopic score of airway inflammation was systematically established by the same investigator. BAL fluid was immediately cooled on ice and processed. For urea and 8-epi-
PGF α, aliquots of 5 mL untreated BAL fluid were stored at -80°C. Supernatant of centrifuged BAL (5 minutes, 2500 x g, 4°C) was snap frozen in liquid nitrogen and stored at -80°C for uric acid analysis. For glutathione analysis, methanol was added to BAL (0.7 mL/mL BAL fluid) which was centrifuged for 2 minutes at 3000 x g and 4°C. Supernatant was withdrawn, snap frozen and stored in liquid nitrogen. The remaining BAL fluid was fixed with ethanol (50%) for cytological analysis.
Standardised Exercise Test
The horses performed for fifty minutes a SET on a treadmill in a ventilated and air conditioned room (ambient temperature 18 ± 3°C, relative humidity 55-60% ). The SET consisted in a warm-up followed by three gallop steps which were interrupted by periods of trot. The SET was finished by a cool down walking. Exercise monitoring was performed at the end of each gallop step by telemetric heart rate recording (Life Scope Monitor, Nihon Kohden, Bretford, Middlesex, UK) and venous lactate determination (Accusport, Boehringer Mannheim, Mannheim, Germany). After the cool down walk, rectal temperature and venous packed cell volume (PCV) were measured.
Analysis of blood samples
All blood samples were analysed within two month following sampling. Plasma urea and uric acid were determined spectrophotometrically by the Sigma kit 66-20 BUN Endpoint and uric acid kit 685 (Sigma Diagnostics, St. Louis, USA), respectively. The haemolysate glutathione was analysed by high performance liquid chromatography (HPLC. Reduced glutathione (GSH), oxidised (GSSG) and total glutathione (TGSH = GSH + GSSG) were determined and glutathione redox ratio (GRR) was calculated (GRR=GSSG/TGSH). Plasma 8-epi-PGF2α was analysed by an EIA kit (R&D Systems, Abingdon UK).
Analysis of bronchoalveolar lavage fluid
All BAL samples were analysed within two month after the protocol. BAL urea was spectrophotometrically determined according to the method of Rennard et al (1986) by use of the Sigma kit 66-20 BUN Endpoint (Sigma Diagnostics, St Louis, USA). Uric acid was
analysed by HPLC. GSH and GSSG in BAL were measured by use of HPLC and GRR was calculated. 8-Epi-PGF2α in BAL was purified and concentrated (C18 column, Bond Elut, Varian, Harbor City, CA, USA) before being analysed by an EIA kit (Cayman, Abingdon, UK). Differential cell count of BAL cells was performed after centrifugation and Papanicolaou staining.
Statistical Analysis
Data are presented as mean ± SD. Each variable of the four datasets corresponding to identical protocol time (Test I, II, III, IV) was analysed for time effect by a one-way analysis of variance. These analyses being non significant, datasets corresponding to identical feeding status were formed : A : before food supplement A or pellet B supplementation, B : after food supplement A supplementation, C : after wash-out, D : after pellet B supplementation. A was considered as pre-treatment reference for B and D in order to minimise baseline value variability. A was then compared with B and D by one-way analysis of variance for assessment of treatment-induced modifications.
Comparisons were performed by considering separately each sampling time (R, Emax, E15 and E6o) or by pooling them. Analysis of variance for repeated measures was performed within each dataset (intra-A, intra-B and intra-C) for analysis of exercise-induced modifications. If significant differences were found, results were compared by a paired
Student's T-test. P < 0.05 was chosen as level of significance.
RESULTS
SET monitoring
The SET monitoring results are shown below.
Table 7 : SET design and monitoring. Values are presented as mean ± SD (n = 8).
Step Speed Slope Duration Dataset Heart Lactate PCV Rectal
SET Rate TO
Unit m-s"1 % minutes Beats/min Mmol-L"1 % °C
1.7 0 all NA NA NA NA
Walk
Trot 3.5 all NA NA NA NA
A 186±11 7.7 ±3.1 .NA NA
Gallop B 181 ±13 7.0 ±3.7 NA NA 1 D 180±16 8.3 ±4.1 NA NA
Trot 3.5 0 all NA NA NA NA
A 196±11 9.7 ± 2.3 NA NA
Gallop B 192 ±13 9.5 ±3.3 NA NA
2 D 192 ±15 10.3 ±3.8 NA NA
Trot 3.5 all NA NA NA NA
A 211 ±9 14.3 ±3.0 NA NA
Gallop 10 B 204 ± 12 13.6 ±2.3 NA NA
3
D 210±16 16.3 ± NA NA
2.3*
Walk 1.7 10 all NA NA NA NA
NA NA 48.1 39.6 ±
SET 0 ±5.5 0.4 end B NA NA 47.4 39.6 ±
±5.7 0.4
D NA NA 48.1 39.7 ±
±6.0 0.6
* significantly higher than B-value (Anova-1, P < 0.05).
A : mean of data recorded prior to commencement of either food supplement A or pellet B treatment
B : data recorded after food supplement A treatment
D : data recorded after pellet B treatment
PCV : packed cell volume, NA : not assessed.
All mean values of heart rate, venous lactate, PCV and rectal body temperature recorded after food supplement A supplementation (B) showed a trend to be lower than those assessed before treatment (A) and after pellet B supplementation (D). Mean venous lactate
recorded at the end of the third gallop of protocol B was significantly lower than that recorded at D, but difference with A was not significant.
Blood markers
Pooled (R, Emax, E15, E60) plasma uric acid levels were significantly lower after food supplement A treatment (B) when compared with pre-treatment (A, P < 0.02) and with pellet B (D, P < 0.005).
There was a trend for haemolysate TGSH (GSH + GSSG) concentrations to be higher after food suppleirient A treatment (B). The E60 GSH increase was more pronounced after food supplement A administration (B). Haemolysate GRR remained unchanged after treatment or exercise.
8-Epi-PGF2α was not modified by either food supplement A (B) or pellet B (D).
Pulmonary markers
By correcting the dilution of the BAL fluid by the urea method the concentrations of BAL uric acid, glutathione and 8-epi-PGF2α were expressed per ml of pulmonary epithelial lining fluid (PELF).
Uric acid concentrations in PELF were not affected by food supplement A freatment, neither at rest, nor after the SET.
Total glutathione levels (GSH + GSSG) in PELF were not sigmficantly affected by food supplement A or pellet B. Exercise-induced decrease of PELF GSH was not significant, but less pronounced in B (food supplement A). Glutathione redox ratio remained unchanged.
Bronchoalveolar Iavage differential cell count and endoscopic inflammatory score
Resting (R) differential cell counts of BAL performed at A, B and C and respective resting (R) and post-exercise (E60) endoscopic inflammatory scores are below.
Table 8 : BAL differential cell count and endoscopic inflammatory score. Values are presented as mean ± SD (n = 8).
Variable Dataset A B D
BAL differential cell count
% Macrophages 38.8 ± 11.8 43.0 ± 5.6 42.6 ± 16.9 % Lymphocytes 45.8 ± 12.3 42.5 ± 12.1 38.9 ± 20.5 % Neutrophils 13.3 ± 17.0 13.4 ± 11.2 13.9 ± 12.8 % Epithelial cells 0.7 ± 1.6 1.9 ± 1.1 1.9 ± 3.2
Inflammatory score
Rest 4 4..3388 ±± 00..5522 3.63 ± 0.52 4.50 ± 0.54 ' Post-exercise E60 5.13 ± 0.99 * 4.13 ± 0.84 4.5 ± 0.54
* significantly higher than B-value (Anova-1, P < 0.05).
A : mean of data recorded prior to commencement of either food supplement A or pellet B treatment (n — 8)
B : data recorded after food supplement A treatment (n = 8) D : data recorded after pellet B treatment (n = 8)
Bronchoalveolar differential cell count was influenced neither by food supplement A (B) nor by pellet B (D).
Resting endoscopic score was significantly lower after food supplement A treatment (B) when compared with pre-treatment values (A) and with pellet B-values (D). Post-exercise scores were non significantly increased in A, B and D. The pre-treatment score (A) was significantly higher than in B.
hi summary, this study has shown that oral antioxidant supplementation may have a beneficial effect on lung function of COPD-affected horses in clinical remission.
Enhanced exercise tolerance, reduction of endoscopic inflammatory score and downregulation of the systemic XDH and XO-pathway with subsequent decreased uric acid synthesis were significant findings in the current study. Pulmonary function tests, BAL cytology, PELF uric acid and PELF 8-epi PCF2α were not influenced by the anti- oxidant supplement treatment but there was a trend towards enhanced systemic and pulmonary GSH restoration after exercise.
Example 2
Determination of the effect of one component of the food supplement (ascorbic acid) on ascorbic acid concentrations in plasma and bronchoalveolar lavage.
This study was carried out using 14 horses; 4 healthy horses and 10 horses suffering from COPD in clinical remission. All horses had been kept continuously on grass for at least 2 months.
Ascorbic acid in bronchoalveolar lavage and plasma were analysed by HPLC using electrochemical detection and UN detection respectively. Bronchoalveolar lavage concentrations of ascorbic acid were corrected to mmol.1"1 of epithelial lining fluid using plasma and bronchoalveolar lavage urea concentrations.
Table 9
These results indicate that ascorbic acid is present in the bronchoalveolar lavage and plasma of healthy horses and horses suffering from COPD. The concentration of ascorbic acid in horses suffering from COPD is lower than that in healthy horses.
The concentration of ascorbic acid in epithelial lining fluid of healthy horses is 20 - 30 times greater than those of reduced glutathione previously reported in horses. Thus it appears that ascorbic acid is a major antioxidant in equine lung fluid lining and horses suffering from COPD appear to have markedly reduced levels in both plasma and bronchoalveolar lavage. COPD horses have shown reduced levels of other antioxidants such as glutathione.
Example 3
Measurement of vitamin C levels in epithelial lining fluid.
Six healthy ponies free of respiratory disease on the basis of endoscopy of the respiratory tract and cytological and bacteriological analysis of tracheal wash and bronchoalveolar lavage (BAL) were studied in a 3 x 3 Latin square design. Ponies were stabled in pairs and fed a diet of haylage to maintain bodyweight and condition. The ponies were allowed access to paddocks whilst muzzled for part of each day.
Ponies were studied in stable pairs and each pair received three treatments: 1) - Control (C); 2) Ascorbyl palmitate (AP; fed at 57.1 mg/day per kg BW); 3) Stabilised ascorbic acid (STAY-C; fed at 57.1 mg/day per kg BW). Doses were chosen to ensure equivalent ascorbic acid levels. Each treatment lasted two weeks and was followed by a washout period of two weeks before the next treatment period. Every two weeks BAL was performed in the right and left lung. On the day following BAL, blood samples were collected before and every hour following feeding up to 8 hours to determine plasma bioavailability.
Both AP and Stay-C produced elevations in plasma ascorbic acid concentration similar to those reported previously in the literature. Peak plasma ascorbic acid concentrations following feeding of AP or Stay-C were seen at around 6-8 hours post-feeding. There was
no change in plasma ascorbic acid over the corresponding period in the control treatment. Both forms of vitamin C also result in increased levels of ascorbic acid in the epithelial lining fluid. These results are illustrated in Figure 1 which indicates the effects of ascorbic acid supplementation on the concentration of ascorbic acid in the epithelial lining fluid.
Example 4
Determination of the effect of the food supplement on ascorbic acid concentrations in plasma and bronchoalveolar lavage.
This study was carried out using a food supplement of the following composition.
Table 10
Five healthy horses free of respiratory disease on the basis of clinical examination and cytological and bacteriological analysis of tracheal wash (TW) and bronchoalveolar lavage (BAL) were studied. They were stabled, bedded on paper and fed a commercial mix and haylage to maintain bodyweight and condition. Prior to the start of the study, the horses performed an incremental exercise test to determine maximum oxygen uptake (NO2max). Throughout the study the horses were exercised three times per week for two minutes at 90% NO2max. Each horse received two treatments in a Latin square design: 1) food supplement, 2) Placebo supplement. Each treatment was given for four weeks and was followed by washout period of our weeks before the next treatment period. Three days prior to the end of each peήod TW and BAL were performed, the latter in the right lung. On the final day of each period the horses performed an exercise test on a 3 incline with the following protocol: lOmin at 1.7m/s, 5min at 3.7m/s, 2min at 70%NO2max, 5min at 1.7m/s, 2min at 80%NO2max, 5min at l.lm/s and 2min at 90%NO2max. Venous blood samples were taken prior to and 60 minutes post exercise. BAL was performed one hour post exercise. Plasma and BAL samples were analysed for ascorbic acid (AA). BAL fluid samples were calculated to give epithelial lining fluid (ELF) concentrations using the urea dilution method. Antioxidant supplementation caused a significant increase in the concentration of plasma AA at rest compared to the pre-supplementation period (p=0.003; 26.2 3.4mol l and 19.2 3.7 mol/1 respectively) but there was no effect of placebo (p>0.05; 19.8 6.9mol/l versus 19.2 3.7mol/l). Resting ELF AA concentration increased following antioxidant supplementation compared to the pre-supplementation period but not significantly (p=0.076; 1.7 *0.8mmol l and w.3 *0.5mmol/l respectively). The placebo supplement did not alter ELF AA (1.2 1. lmmol/1 versus 1.3 *0.5rhmol/l). Neither plasma nor ELF AA were significantly changed one hour after the exercise test compared to resting concentrations after either the antioxidant supplement or the placebo. In summary, antioxidant supplementation caused increases in plasma levels of ascorbic acid and in ELF ascorbic acid levels.
Claims
Claims
1 A food supplement comprising one or more antioxidant vitamin with one or more of eugenol, a flavenoid, a phyto-estrogen, a proanthrocyandin, selenium or ubiquinone, a carotenoid or a herbal phenolic.
2 A food supplement as claimed in claim 1 wherein the antioxidant vitamin is one or more of vitamin C, vitamin E or beta-carotene.
3 A food supplement as claimed in claim 1 or claim 2 further comprising a B vitamin.
4 A food supplement as claimed in claim 3 wherein the B vitamin is one or more of vitamin B-l, vitamin B-2, vitamin B-3, vitamin B-6, vitamin B-12, pantotheic acid or folate.
5 A food supplement as claimed in anyone of claims 1 to 4 further comprising one or more trace element.
6 A food supplement as claimed in claim 5 wherein the trace element is one or more of iron, zinc, copper, magnesium, manganese or calcium.
7 A food supplement as claimed in any one of claims 1 to 6 which provides a concentration of vitamin E at a level of 5IU per kilogram body weight per day or above.
8 A food supplement as claimed in any one of claims 1 to 7 which provides a concentration of vitamin C at a level of lOmg per kilogram body weight per day or above.
9 A food supplement as claimed in any one of claims 1 to 8 which provides a concentration of beta-carotene at a level of 0.3mg per kilogram body weight per day or above.
10 A food supplement as claimed in any one of claims 1 to 9 which provides a concentration of selenium at a level of 0.002mg per kilogram body weight per day or above.
11 A food supplement as claimed in anyone of claims 1 to 10 which provides a concentration of ubiquinone at a level of 0.5mg per kilogram body weight per day or above.
12 A food supplement as claimed in any one of claims 1 to 11 which provides a concentration of folate at a level of 0.02mg per kilogram body weight per day or above.
13 A food supplement wherein each component of the food supplement as set out in anyone of claims 1 to 12 is provided by a synthetic source or a natural source.
14 A food supplement as claimed in anyone of claims 1 to 13 wherem a portion of the antioxidant vitamin is provided by a natural source and a portion of the antioxidant vitamin is provided by a synthetic source.
15 A food supplement as claimed in any one of claims 1 to 14 wherein one or more of eugenol, a flavenoid, a phyto-estrogen, a proanthrocyandin, a carotenoid, a herbal phenohc, selenium or ubiquinone is provided by a natural source and a synthetic source.
16 A food supplement as claimed in anyone of claims 1 to 15 wherein vitamin C is provided as Stay-C or ascorbyl palmitate.
17 A food supplement as claimed in anyone of claims 1 to 16 wherein vitamin E is provided as alpha -tocopherol or alpha-tocopherol acetate.
18 A food supplement as claimed in any one of claims 1 to 17 wherein part of vitamin C or vitamin E is provided by one or more of broccoli, spinach, cabbage, cauliflower, brussel sprouts, kale or chard.
19 A food supplement as claimed in claim 17 wherein the source of vitamin C or vitamin E is raw, cooked, or dried material.
20 A food supplement as claimed in any one of claims 1 to 19 which provides a concentration of broccoli at a level of 20mg per kilogram body weight per day or above.
21 A food supplement as claimed in any one of claims 1 to 20 which provides a concenfration of spinach at a level of 20mg per kilogram body weight per day or above.
22 A food supplement as claimed in anyone of claims 1 to 21 wherein one or more of caretonoids or vitamin E is provided by red palm oil.
23 A food supplement as claimed in anyone of claims 1 to 22 wherein a phyto- estrogen is provided by one or more of broccoli, spinach, cabbage, cauliflower, brussel sprouts, kale or chard.
24 A food supplement as claimed in anyone of claims 1 to 23 wherein eugenol is provided by one or more of garlic, cloves or nutmeg.
25 A food supplement as claimed in any one of claims 1 to 24 wherein a flavenoid is provided by one or more of rosemary or liquorice.
26 A food supplement as claimed in any one of claims 1 to 25 wherein a herbal phenolic is provided by rosemary.
27 A food supplement as claimed in any one of claims 3 to 26 wherein one or more of vitamin E or proanthrocyanidin is provided by grape seed oil.
28 A food supplement as claimed in any one of claims 1 to 26 wherein selenium is provided by sodium selenate.
29 A food supplement as claimed in any one of claims 1 to 28 wherein selenium is provided by one or more of broccoli, spinach, cabbage, cauliflower, brussel sprouts, kale or chard.
30 A food supplement as claimed in claim 3 wherein the B vitamin is provided by one or more of broccoli, spinach, cabbage, cauliflower, brussel sprouts, kale or chard.
31 A food supplement as claimed in claim 3 wherein the B vitamin is provided by Brewers yeast.
32 A food supplement as claimed in claim 31 which provides a concentration of brewers yeast at a level of 20mg per kilogram body weight per day or above.
33 A food supplement as claimed in anyone of claims 1 to 32 which provides a concentration of eugenol at a level of 0. lmg per kilogram body weight per day or above.
34 A food supplement as claimed in any one of claims 1 to 33 for use in achieving a health benefit.
35 A food supplement as claimed in anyone of claims 1 to 34 for use in maintaining or improving the natural defences of the lung.
36 A food supplement as claimed in any one of claims 1 to 34 for use in combination with a conventional therapy for the prevention or treatment of respiratory disease.
37 A food supplement as claimed in any one of claims 1 to 36 for use in aiding the prevention or treatment of oxidative damage.
38 A food supplement as claimed in any one of claims 1 to 37 for use in aiding the prevention or treatment of oxidative damage in the respiratory tract.
39 A food supplement as claimed in any one of claims 1 to 38 for use aiding in the prevention or treatment of respiratory disease.
40 A food supplement as claimed in anyone of claims 1 to 39 for simultaneous, sequential or separate use in aiding the prevention or freatment of respiratory disease.
41 A food supplement for use as claimed in any one of claims 39 or 40 wherein the respiratory disease is chronic obstructive pulmonary disease.
42 A food supplement comprising vitamin C for use in the prevention or treatment of a respiratory disease.
43 A food supplement as claimed in any one of claims 1 to 42 wherein the food supplement is administered to an equine animal.
44 A food supplement as claimed in claim 43 wherein the equine animal is a horse.
45 Use of a food supplement as claimed in any one of claims 1 to 33 for the manufacture of a medicament or food stuff for aiding the prevention or treatment of oxidative damage.
46 Use of a food supplement as claimed in any one of claims 1 to 33 for the manufacture of a medicament or food stuff for aiding the prevention or treatment of respiratory disease.
47 A method of aiding the prevention or treatment of oxidative damage, the method comprising administering to the animal a food supplement as claimed in any one of claims
1 to 33.
48 A method of aiding the prevention or treatment of respiratory disease, the method comprising administering to the animal a food supplement as claimed in any one of claims 1 to 33.
49 A food stuff comprising a food supplement as claimed in claims 1 to 33.
50 A method for making a foodstuff as claimed in claim 49, the method comprising mixing one or more component of the food supplement as claimed in claims 1 to 33 with a conventional food stuff.
51 A food stuff as claimed in claim 49 for use in medicine.
52 A food stuff as claimed in claim 51 wherein the use is aiding the prevention or treatment of a respiratory disease.
53 A food supplement as claimed in any one of claims 1 to 33 or a food stuff as claimed in claim 49 wherein the food supplement or food stuff is administered to an animal as an ergogenic aid.
54 A method of improving or increasing the work production of an animal comprising administering a food supplement as claimed in any one of claims 1 to 33 or a food stuff as claimed in claim 49.
55 A food supplement as claimed in any one of claims 1 to 33 or a food stuff as claimed in claim 49 for use in the preparation of an ergogenic aid.
56 A food supplement as claimed in any one of claims 53 to 55 wherein the animal is an equine animal.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0023354 | 2000-09-22 | ||
GB0023354A GB0023354D0 (en) | 2000-09-22 | 2000-09-22 | Food supplement |
GB0116048 | 2001-06-29 | ||
GB0116048A GB0116048D0 (en) | 2001-06-29 | 2001-06-29 | Food supplement |
PCT/GB2001/004230 WO2002024002A2 (en) | 2000-09-22 | 2001-09-21 | Food supplement |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1322175A2 true EP1322175A2 (en) | 2003-07-02 |
Family
ID=26245044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01967544A Withdrawn EP1322175A2 (en) | 2000-09-22 | 2001-09-21 | Food supplement |
Country Status (11)
Country | Link |
---|---|
US (1) | US20040115309A1 (en) |
EP (1) | EP1322175A2 (en) |
JP (1) | JP2004530407A (en) |
AU (2) | AU8791701A (en) |
BR (1) | BR0114080A (en) |
CA (1) | CA2422819C (en) |
GB (1) | GB2369549B (en) |
MX (1) | MXPA03002551A (en) |
NZ (1) | NZ524869A (en) |
PL (1) | PL362120A1 (en) |
WO (1) | WO2002024002A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6488957B1 (en) * | 2001-12-17 | 2002-12-03 | Teddy A. Koumarianos | Food additive composition |
GB0202258D0 (en) * | 2002-01-31 | 2002-03-20 | Dodson & Horrell Ltd | Annimal feed supplement |
JP4532811B2 (en) * | 2002-03-20 | 2010-08-25 | 株式会社ファンケル | Female hormone-like agent |
JP2003325135A (en) * | 2002-05-08 | 2003-11-18 | Toyo Shinyaku:Kk | Health food |
GB0218932D0 (en) * | 2002-08-14 | 2002-09-25 | Zoolife Internat Ltd | Composition for dietary enrichment |
CA2833559A1 (en) * | 2003-02-14 | 2004-09-02 | Children's Hospital & Research Center At Oakland | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
US8034372B2 (en) * | 2003-03-05 | 2011-10-11 | Nestec, Ltd. | Dietary supplement for athletic pets |
US7824706B2 (en) * | 2003-05-09 | 2010-11-02 | Freedom Health, Llc | Dietary supplement and method for the treatment of digestive tract ulcers in equines |
US7658964B2 (en) * | 2003-05-09 | 2010-02-09 | Freedom Health, Llc | Dietary supplement and method for increasing the colostrum immunoglobulin levels in equine mares |
AU2004268380A1 (en) * | 2003-09-02 | 2005-03-10 | Dsm Ip Assets B.V. | Method of stabilizing ascorbyl phosphate and salts thereof |
JP4247833B2 (en) * | 2004-03-16 | 2009-04-02 | 株式会社ケーツーコミュニケーションズ | Visual function improver |
EP1755406B1 (en) * | 2004-04-16 | 2012-09-26 | Nestec S.A. | Compositions for reducing oxidative stress in an animal |
JP2006212019A (en) * | 2004-04-30 | 2006-08-17 | National Institute Of Agrobiological Sciences | Method for producing ubiquinone-10 using plant |
JP2006014730A (en) * | 2004-05-31 | 2006-01-19 | Toyo Shinyaku:Kk | Food product |
JP4896531B2 (en) * | 2005-01-25 | 2012-03-14 | 第一三共ヘルスケア株式会社 | Pharmaceutical composition for increasing blood CoQ10 level |
US9095164B2 (en) * | 2005-02-09 | 2015-08-04 | Kevin Meehan | Animal feed composition for increased production of glutathione peroxidase and superoxide dismutase |
US20080138483A1 (en) * | 2005-02-09 | 2008-06-12 | Kevin Meehan | Animal feed composition for increased bioactivity and production of glutathione peroxidase and superoxide dismutase |
AU2006227165B2 (en) | 2005-03-18 | 2011-11-10 | Microbia, Inc. | Production of carotenoids in oleaginous yeast and fungi |
US20070042972A1 (en) * | 2005-05-24 | 2007-02-22 | Mckeever Kenneth H | Compositions and methods for optimizing exercise recovery |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
CA2635518A1 (en) * | 2005-12-27 | 2007-07-05 | Apt Co., Ltd. | Agent for prophylactic and/or therapeutic treatment of chronic obstructive pulmonary disease |
MY161865A (en) * | 2006-02-10 | 2017-05-15 | Mannatech Inc | All natural multivitamin and multimineral dietary supplement formulations for enhanced absorption and biological utilization |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
US8691555B2 (en) | 2006-09-28 | 2014-04-08 | Dsm Ip Assests B.V. | Production of carotenoids in oleaginous yeast and fungi |
US20080146579A1 (en) * | 2006-12-15 | 2008-06-19 | N.V. Nutricia | Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore |
JP2009062330A (en) | 2007-09-07 | 2009-03-26 | Fujifilm Corp | Powder composition |
US20100178369A1 (en) * | 2009-01-15 | 2010-07-15 | Nicole Lee Arledge | Antioxidant-stabilized concentrated fish oil |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
CN102333529A (en) * | 2009-02-27 | 2012-01-25 | 三菱瓦斯化学株式会社 | Coenzyme q10-containing composition for oral ingestion |
EP2308489B1 (en) * | 2009-10-05 | 2014-01-01 | Nutri-Fit GmbH & Co. KG | Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock |
TWI492744B (en) * | 2009-12-04 | 2015-07-21 | Abbott Lab | Methods of modulating inflammation in preterm infants using carotenoids |
DE102009058325A1 (en) * | 2009-12-15 | 2011-06-16 | Henning Vollert | Extract of a plant of Brassica, useful for increasing antioxidant activity of epithelial tissue e.g. epithelial tissue of skin or preventing and treating eye diseases e.g. macular degeneration or cataract and preventing eating disorders |
US8916528B2 (en) | 2011-11-16 | 2014-12-23 | Resveratrol Partners, Llc | Compositions containing resveratrol and nucleotides |
US20140271594A1 (en) * | 2013-03-16 | 2014-09-18 | Stephen T. Sinatra | Equine supplement |
US20150056176A1 (en) * | 2012-01-18 | 2015-02-26 | Stanley N. Jankowitz | Anti-inflammatory composition |
WO2014013068A1 (en) * | 2012-07-20 | 2014-01-23 | Dr. Eckel Gmbh | Combination for reducing methane emissions in ruminant feeding |
GB201302755D0 (en) | 2013-02-15 | 2013-04-03 | Mars Inc | Horse supplement |
CA2916759C (en) | 2013-08-08 | 2023-02-28 | Knipbio | Methylotrophs for aquaculture and animal feed |
MX2016007340A (en) | 2013-12-06 | 2016-12-14 | Dsm Ip Assets Bv | Biomass formulation. |
WO2016037166A1 (en) * | 2014-09-07 | 2016-03-10 | Yu Zhang | Novel anti-oxidant compositions and methods of delivery |
CA3013705A1 (en) * | 2016-02-05 | 2017-08-10 | Merial, Inc. | Antioxidants against oxidative stress during a stressor event |
CN106478579B (en) * | 2016-08-30 | 2019-04-09 | 浙江工业大学 | A kind of procyanidine and its application extracted from fresh perilla stem and leaves |
CN107259216B (en) * | 2017-07-05 | 2018-09-14 | 云南农业大学 | A kind of fish feed ready-mixed oil with anti-oxidation function |
WO2019204381A1 (en) * | 2018-04-19 | 2019-10-24 | BIDNER, Daniel | Veterinary thick gel composition of high palatability containing antioxidants to decrease sarcopenia, osteopenia and dna damage from oxidative stress in dogs, and procedure for its obtention |
US20220256890A1 (en) * | 2019-07-10 | 2022-08-18 | Mootral Innovations Limited | Animal feed supplement and animal feed composition |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5141755A (en) * | 1991-05-29 | 1992-08-25 | Weisman Eric H | Reduced animal product pet food composition |
NZ238825A (en) * | 1991-07-03 | 1994-03-25 | Ultimate Equine Limited Substi | Food supplement containing selenium, germanium, and at least vitamins a and e |
US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
US5656312A (en) * | 1994-09-02 | 1997-08-12 | Erasmus; Udo | Dietary food supplement and method of preparing |
US6440464B1 (en) * | 1996-06-10 | 2002-08-27 | Viva Life Science | Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates |
AU3582597A (en) * | 1996-06-28 | 1998-01-21 | Viva America Marketing, Inc. | Nutritional supplement composition and use |
US5837252A (en) * | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
JP3923603B2 (en) * | 1996-07-17 | 2007-06-06 | 日清丸紅飼料株式会社 | Pig farm feed |
US5895652A (en) * | 1996-07-29 | 1999-04-20 | Longevity Institute International | Method of metabolic adjuvanation and cellular repair |
US5985339A (en) * | 1996-11-22 | 1999-11-16 | Kamarei; A. Reza | Refrigeration-shelf-stable ready-to-drink complete nutritional compositions and products |
US5937790A (en) * | 1996-12-18 | 1999-08-17 | Showa Denko Kabushiki Kaisha | Anti-stress agent for animals and a method of reducing stress in animals |
US5976568A (en) * | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
WO1998043617A2 (en) * | 1997-03-27 | 1998-10-08 | Sole Michael J | Nutritional composition for improvements in cell energetics |
DE59712694D1 (en) * | 1997-04-18 | 2006-08-24 | Fritz Stanislaus | STABILIZED MEDICAMENT CONTAINING CYSTEINYL DERIVATIVES |
GB9715203D0 (en) * | 1997-07-19 | 1997-09-24 | Piper Edwina M | Composition |
US5904924A (en) * | 1997-11-04 | 1999-05-18 | Oncologics, Inc. | Green nutritional powder composition |
US5922346A (en) * | 1997-12-01 | 1999-07-13 | Thione International, Inc. | Antioxidant preparation |
US6004560A (en) * | 1998-11-16 | 1999-12-21 | Hsu; Wu-Ching | Nasal spray (drop) for treating fever/cold, and its preparation |
US6391330B1 (en) * | 2000-05-11 | 2002-05-21 | Michael A. Ross | Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa |
DE60027415T2 (en) * | 2000-06-16 | 2006-10-19 | Rath, Matthias, Dr.med. | A smooth muscle disease prevention composition containing ascorbate, arginine and magnesium |
-
2001
- 2001-09-21 CA CA002422819A patent/CA2422819C/en not_active Expired - Lifetime
- 2001-09-21 JP JP2002528047A patent/JP2004530407A/en not_active Withdrawn
- 2001-09-21 WO PCT/GB2001/004230 patent/WO2002024002A2/en not_active Application Discontinuation
- 2001-09-21 BR BR0114080-9A patent/BR0114080A/en not_active Application Discontinuation
- 2001-09-21 EP EP01967544A patent/EP1322175A2/en not_active Withdrawn
- 2001-09-21 NZ NZ524869A patent/NZ524869A/en not_active IP Right Cessation
- 2001-09-21 AU AU8791701A patent/AU8791701A/en active Pending
- 2001-09-21 US US10/381,266 patent/US20040115309A1/en not_active Abandoned
- 2001-09-21 GB GB0122855A patent/GB2369549B/en not_active Expired - Lifetime
- 2001-09-21 PL PL36212001A patent/PL362120A1/en not_active Application Discontinuation
- 2001-09-21 AU AU2001287917A patent/AU2001287917B2/en not_active Expired
- 2001-09-21 MX MXPA03002551A patent/MXPA03002551A/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0224002A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002024002A2 (en) | 2002-03-28 |
AU8791701A (en) | 2002-04-02 |
US20040115309A1 (en) | 2004-06-17 |
JP2004530407A (en) | 2004-10-07 |
GB2369549B (en) | 2003-12-10 |
GB0122855D0 (en) | 2001-11-14 |
GB2369549A (en) | 2002-06-05 |
MXPA03002551A (en) | 2004-08-12 |
PL362120A1 (en) | 2004-10-18 |
NZ524869A (en) | 2005-06-24 |
WO2002024002A3 (en) | 2002-08-22 |
CA2422819C (en) | 2008-07-08 |
BR0114080A (en) | 2003-07-29 |
CA2422819A1 (en) | 2002-03-28 |
AU2001287917B2 (en) | 2007-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2422819C (en) | Food supplement | |
AU2001287917A1 (en) | Food supplement | |
US10583164B2 (en) | Compositions including ginger for the amelioration or prevention of inflammatory conditions | |
US20220296552A1 (en) | Compositions and methods for acutely raising nitic oxide levels | |
Pereira et al. | Banana (Musa spp) from peel to pulp: ethnopharmacology, source of bioactive compounds and its relevance for human health | |
US12053003B2 (en) | Animal feed supplement | |
RU2744134C2 (en) | Nutritional compositions for heart protection in companion animals | |
US20010043983A1 (en) | Nutritional supplements for aged pets | |
US20030060503A1 (en) | Nutritional supplements for mature pets | |
EP1581199B1 (en) | Orally administrable composition for improving skin quality | |
US20190240180A1 (en) | Mct-based nutrition blend for providing health benefits in companion animals | |
GB2385254A (en) | Food supplement | |
ZA200302701B (en) | Food supplement. | |
KR20110057480A (en) | Vitamin tablet comprising vitamin c mixture | |
US20240115540A1 (en) | Methods for providing health benefits in animals | |
Bilal et al. | The effect of vitamin E supplementation on chronic N0∼ 2, toxication in broiler chicken | |
Thompson | Vitamins, minerals and supplements 5: overview of vitamin C | |
Foods | The Benefits of Whole Food Nutrition in Veterinary Medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030414 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
17Q | First examination report despatched |
Effective date: 20050701 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20061017 |